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Molecular pathways involved in injury-repair and 
ADPKD progression
Chiara Formica1 and Dorien J.M. Peters1




1. Autosomal Dominant Polycystic Kidney Disease
Autosomal	Dominant	Polycystic	Kidney	Disease	(ADPKD)	is	a	heritable	genetic	disorder	with	




















influencing	 several	 signalling	 pathways4,6.	 However,	 the	molecular	mechanisms	 that	 lead	
to	 cyst	 initiation	and	progression	after	 the	 loss	of	 functional	 levels	of	PC1/2	are	 still	not	
understood.







several	 studies,	 differences	 in	 timing	 and	 location	 of	 gene	 inactivation,	 the	 metabolic	
status,	the	genetic	context	and	introduction	of	renal	injury	can	influence	cyst	formation	and	





in	 local	 injury	 and	 fibrosis13.	 In	 the	 advanced	 stages	 of	 the	 disease,	 cystic	 kidneys	 are	
characterised	by	 local	 injury,	production	of	growth	factors	and	cytokines,	 infiltrating	cells	
and	progressive	fibrosis,	which	ultimately	lead	to	loss	of	renal	function11.
Figure 1. Disease progression in ADPKD




other	events,	 for	example,	 renal	 injury.	After	 injury,	 the	 tissue	 repair	occurs	 in	 the	absence	of	 sufficient	 levels	
of	PC1/2	resulting	in	an	abnormal	tubular	epithelium.	The	structurally	altered	epithelial	cells	are	more	prone	to	
cyst	formation,	accelerating	disease	progression.	After	cysts	are	formed,	increased	proliferation	and	altered	fluid	




2. Renal injury and repair mechanisms 
Following	a	renal	 insult,	 the	kidneys	are	able	to	repair	 the	 injury	themselves	by	 inducing	
proliferation	of	surviving	tubular	epithelial	cells14.	During	this	regeneration	phase,	tubular	
epithelial	 cells	 are	 lost	 or	 show	an	 aberrant	morphology	 (e.g.,	 loss	 of	 brush	 border	 and	
flattening	 of	 proximal	 tubular	 epithelial	 cells).	 Also,	 infiltration	 of	 inflammatory	 cells	
is	observed15.	All	 these	events	ensure	a	proper	 repair	of	 kidney	 structures	and	 function.	
However,	 in	some	cases	the	damage	is	too	extensive,	or	the	 injury	 insult	persists	 leading	
to	tissue	remodelling,	progressive	fibrosis	and	loss	of	renal	function.	This	fibrotic	phase	is	











levels	 of	 PC1	might	 trigger	 the	 activation	 of	 proliferation	 even	 in	 the	 absence	 of	 injury,	
resulting	 in	 cyst	 growth	 and	 expansion17.	 However,	 especially	 in	 adult	 kidneys,	 deletion	
of Pkd1	 alone	does	not	 immediately	 translate	 in	 cyst	 formation,	which	occurs	only	 after	
a	 lag	period.	Another	event,	such	as	renal	 injury,	must	occur	to	start	cyst	 formation17.	 In	
line	with	this	idea,	several	research	groups	employing	different	kinds	of	renal	injury	(e.g.,	
nephrotoxic	 compound,	 ischemia-reperfusion	 or	 unilateral	 nephrectomy)	 demonstrated	




Interestingly,	 various	mechanisms	normally	 active	during	 the	 injury-repair	 phase	 such	as	
proliferation,	inflammation,	cell	differentiation,	cytokines	and	growth	factors	secretion,	are	
also	 activated	during	 PKD	progression,	 and	 largely	 overlap	with	 the	mechanisms	 at	 play	
during	renal	development17,22-24.	In	fact,	renal	epithelial	cells	in	ADPKD	kidneys	often	appear	






tissues,	 in	 line	with	 the	partial	 dedifferentiated	phenotype	observed27.	 Altogether,	 these	
events	can	ultimately	contribute	to	disease	progression.	In	a	normal	situation,	reactivation	






































Figure 2. The evolution of injury in normal and Pkd1 deficient kidneys 
a)	After	injury,	the	renal	epithelium	can	regenerate	the	damaged	and	lost	tissue.	This	phase	is	characterised	by	the	
dedifferentiation	and	proliferation	of	epithelial	cells,	as	well	as	the	recruitment	of	leucocytes	and	the	activation	
of	 fibroblasts	 in	 myofibroblasts.	When	 all	 these	 processes	 work	 harmoniously,	 the	 tissue	 is	 restored	 and	 the	











3.1 Injury-repair and fibrosis
3.1.1 Renal injury
Repair	after	 renal	 injury	 relies	on	 the	surviving	epithelial	 cells,	which	can	dedifferentiate	
to	 be	 able	 to	 spread	 and	migrate	 to	 cover	 exposed	 tubular	 tracts	 and	 to	 proliferate	 in	
order	to	restore	the	integrity	of	the	tissue.	Indeed,	injured	kidneys	are	strongly	positive	for	
proliferation	markers	such	as	Ki67	and	proliferative	cell	nuclear	antigen	(PCNA)28,29.	Once	
the	 integrity	of	 the	 tubules	 is	 restored,	 cells	need	 to	differentiate	back	 into	 fully	mature	
epithelial	 cells	 to	 re-establish	 the	 proper	 function	 of	 the	 organ.	 It	 has	 been	 proposed	
that	 laminin-integrin	 interactions	 might	 drive	 re-differentiation	 of	 the	 epithelium.	 In	
particular,	 laminin-5	 and	 α3β1-integrin	 expression	 are	 increased	 after	 ischemic	 kidney	
injury30.	Interestingly,	laminin-5	expression	is	also	increased	in	the	ECM	of	ADPKD	kidneys.	







This	 is	 necessary	 for	 cell	 proliferation	 and	 repair	 of	 the	 tubule33.	 The	 TGF-β	 superfamily	
of	proteins	comprises	a	group	of	highly	conserved	secreted	morphogens,	which	regulate	
a	 variety	 of	 developmental	 and	 homeostatic	 processes.	 Upon	 binding	 of	 the	 TGF-β	
family	members	to	their	receptors,	a	series	of	phosphorylation	events	are	triggered.	The	
signalling	 cascade	 ends	 up	 with	 the	 phosphorylation	 and	 subsequent	 activation	 of	 the	
SMAD	transcription	 factors,	which	 translocate	 to	 the	nucleus	where	 they	can	drive	gene	
expression34.	Thus,	TGF-β	can	suppress	 the	expression	of	epithelial	markers	and	 increase	
the	expression	of	mesenchymal	markers,	 such	 as	αSMA	and	 vimentin,	 leading	 to	partial	
dedifferentiation,	 i.e.	 epithelial-to-mesenchymal	 transition	 (EMT).	 Although	 EMT	 is	 a	
physiological	 event	 during	 renal	 development	 and	 useful	 adaptive	 response	 to	 injury,	
sustained	 EMT	 can	 result	 in	 increased	 matrix	 deposition	 and	 cytokine	 production	 that	
lead	 to	 CKD.	 Moreover,	 TGF-β	 can	 stimulate	 ECM	 deposition	 by	 acting	 directly	 on	 the	
transcription	of	fibronectin,	proteoglycans,	collagens	and	integrins.	At	the	same	time,	TGF-β	
antagonises	matrix	degradation	by	stimulating	proteases	inhibitors	production35.	In	line	with	
these	findings,	several	in vivo and in vitro	experiments	have	shown	that	TGF-β	might	be	the	
mediator	of	AKI-to-CKD	progression36.	
3.1.2 PKD








Increased	 TGF-β	 and	 nuclear	 phospho-SMAD2	 staining	 are	 often	 observed	 in	 cyst-lining	
epithelium	and	interstitial	cells	surrounding	cysts,	both	in	mice	and	humans38.	Shear	stress,	
induced	by	fluid	flow,	on	wildtype	and	Pkd1-/- tubular	epithelial	cell	cultures	activates	the	














the	context,	 cell	 types	and	 the	cofactors	 involved	 shape	 the	outcome	of	 the	 signalling34.	
Hence,	further	studies	to	investigate	the	role	and	the	possible	use	of	TGF-β	as	a	therapeutic	
target	in	ADPKD	are	needed.





a	 known	driver	of	fibrotic	 response	 in	CKD46.	 In	ADPKD,	 cyst	 formation	and	expansion	 is	
associated	with	 altered	 vascular	 architecture.	 In	 particular,	 peritubular	microvasculature	
shows	signs	of	regression	of	larger	capillaries	together	with	flattened	arterioles	and	atresic	




polycystins	 in	 the	 vasculature	where	 they	 have	 crucial	 roles	 in	mechanosensation,	 fluid-
shear stress sensing, signalling and maintaining structural integrity48-52.	 Regardless	 of	
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to	 the	tissue	damage.	 Injured	 tubular	epithelial	 cells	 release	pro-inflammatory	 cytokines	
and	 chemokines,	 growth	 factors	 and	 adhesion	 molecules,	 such	 as	 interleukin-1	 (IL-1),	
tumour	necrosis	 factor-alpha	 (TNF-α),	monocyte	 chemoattractant	protein-1	 (MCP-1)	 and	













transcription	 of	 pro-inflammatory	 genes	 that	 encodes	 for	 cytokines	 and	 growth	 factors,	



























function	 in	 different	 mouse	 models67,68.	 Additionally,	 deletion	 of	 macrophage	 migration	
inhibitory	 factor	 (Mif)	or	pharmacological	 inhibition	of	MIF,	which	 is	upregulated	 in	cyst-
lining	 cells	 and	 is	 responsible	 for	 macrophage	 recruitment,	 resulted	 in	 reduced	MCP-1-
dependent	macrophage	accumulation	 in	 the	cystic	kidneys	and	subsequent	delay	of	cyst	
growth	 in	 several	PKD	mouse	models69.	 Since	comparable	 results	were	observed	 in	both	
orthologous	(with	a	Pkd1/2	mutant	gene)	and	non-orthologous	models	(with	mutations	in	




microcysts, and in vivo	they	might	have	increased	the	tubular	proliferation	observed	after	










TNF-α	 developed	 several	 cyst-like	 structures.	 In vivo,	 intraperitoneal	 injections	 of	 TNF-α	
increased	the	incidence	of	cyst	formation	in	Pkd2+/-	mice	of	8.5	weeks	of	age.	Additionally,	
also TNF-α	receptor	-I	and	-II,	and	TNF-α	converting	enzyme	(TACE)	are	enriched	in	human	















tubules.	 Subsequently,	 these	macrophages	differentiated	 to	M2-like	macrophages,	which	
stimulate	 tubules	 proliferation	 and	 cyst	 growth80.	 Genetic	 deletion	 of	 Mcp-1 together 
with	Pkd1,	as	well	as	administration	of	an	MCP-1	receptor	inhibitor,	reduced	macrophage	
infiltration,	 cyst	 growth	 and	 improved	 renal	 function	 and	 survival80.	 Therefore,	 targeting	
macrophage	 recruitment	 and	 activation	 might	 be	 a	 promising	 therapeutic	 approach	 in	
ADPKD.	However,	administration	of	an	 inhibitor	of	MCP-1	synthesis	 in	a	non-orthologous	
model	of	PKD	 in	 rats	was	able	 to	 reduce	 interstitial	 inflammation	but	did	not	affect	 cyst	
formation,	questioning	the	importance	of	the	MCP-1-recruited	inflammatory	infiltrates	in	
cysts	initiation81.











In	 agreement	 with	 these	 findings,	 NF-κB	 pathway	 inhibition	 using	 anti-inflammatory	
compounds	successfully	ameliorated	PKD	progression	in	animal	models,	indicating	that	NF-
κB	 is	a	viable	 target	 for	 therapy60,89-91.	However,	more	studies	are	needed	to	characterise	
the	role	of	 this	pathway	 in	 inflammation	 in	the	context	of	ADPKD.	Another	 link	between	
inflammation	and	ADPKD	is	the	JAK-STAT	pathway.	After	an	injury	in	normal	cells,	changes	










































EGF,	 TGF-α	 and	HB-EGF106,107.	 Transgenic	 overexpression	of	Tgf-α in mice resulted in cyst 
formation	 and	 accelerated	 PKD	 progression	 in	 pcy	 mice	 (non-orthologous	 model	 with	
mutation	 in	 the	Nphp3	gene)108,109.	Moreover,	 these	 ligands	are	 found	abundantly	 in	cyst	
fluid	of	ADPKD	patients,	and	stimulation	of	cultured	epithelial	cells	with	cysts	fluid	promotes	
cyst	 formation	and	expansion	 in vitro110.	 Interestingly,	 cystic	epithelial	 cells	 isolated	 from	
ADPKD	patients	are	more	 responsive	 to	 the	proliferative	 stimulus	of	EGF111.	Additionally,	
the	 EGF	 family	 ligands	 receptors	 (EGFR)	 are	 expressed	at	 the	basal	 side	of	 normal	 adult	















Also,	other	GFs,	 including	 IGF1,	HGF,	VEGF,	PDGF,	FGF	and	CTGF	have	been	described	 to	
be	 involved	 in	ADPKD.	 Increased	gene	expression	of	 IGF1	and	other	 IGF	 family	members	
is	 observed	 in	 murine	 and	 human	 renal	 cysts	 and	 is	 associated	 with	 hyperproliferation	
of	Pkd1	mutant	cystic	cells55,117.	HGF	and	its	receptor,	the	tyrosine	kinase	receptor	c-Met,	





































cells	 in	 the	cystic	epithelium.	As	a	 result,	EGF	secreted	 in	 the	 lumen	of	 the	cysts	can	 interact	with	 its	 receptor	
establishing	 an	autocrine	and	paracrine	 loop	 that	drives	proliferation	and	 cyst	 expansion.	Another	well-known	
GF	 in	PKD	 is	TGF-β.	Cystic	epithelial	cells	often	show	increased	TGFβ	expression	and	nuclear	phopspho-SMAD2	













Other	GFs	 involved	 in	ADPKD,	 such	as	PDGF,	 FGF	and	CTGF,	 showed	an	effect	mainly	on	
interstitial	 cells	 (Figure	 4).	 PDGF	 expression,	 especially	 PDGF-B,	 was	 found	 in	 cyst-lining	
epithelial	cells	using	immunohistochemistry	in	a	human	ADPKD	kidney124.	However,	PDGF	
did	not	 show	a	mitogenic	effect	on	epithelial	 cells	 in vitro	but	was	able	 to	 stimulate	 the	
proliferation	 of	 ADPKD-derived	 fibroblasts	 in vitro	 more	 effectively	 than	 with	 healthy-
derived	fibroblasts125.	A	 similar	effect	was	observed	upon	FGF	 stimulation,	which	 caused	
ADPKD-derived	fibroblasts	 to	 proliferate	more,	 produce	 and	 release	more	 FGF	 and	elicit	
a	 more	 consistent	 and	 lasting	 tyrosine	 phosphorylation	 signalling	 cascade	 compared	 to	
normal	renal	fibroblasts126.	CTGF	is	most	known	for	its	role	as	a	driver	of	interstitial	fibrosis	







CTGF	 therapies	using	 a	human	monoclonal	 antibody	 that	 targets	CTGF	have	 successfully	





Overall,	 GFs	 secreted	 by	 cystic	 tubular	 epithelial	 cells	 trigger	 surrounding	 epithelial	 and	
interstitial	cells	to	produce	proliferative	and	profibrotic	factors,	which	regulate	cyst	growth	
and	interstitial	fibrosis	observed	in	ADPKD	progression.




these	 evolutionarily	 conserved	 pathways	 are	 regulated	 and	 signal	 through	 different	
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routes,	 they	have	 in	common	a	role	 in	renal	development,	and	 illustrate	the	reactivation	
of	 developmental	 pathways	 in	 the	 injury-repair	 response24,135.	 However,	 prolonged	
activation	of	 these	developmental	pathways	due	to	chronic	or	 repetitive	 injury	may	 lead	




share common molecular mechanisms55.
3.4.1 Notch signalling pathway
3.4.1.1 Renal injury
Notch	 pathway	 controls	 cell	 proliferation,	 differentiation	 and	 cell	 fate138.	 During	 renal	












components	 in	mouse	and	human	ADPKD	kidneys	revealed	 increased	expression	 in	cysts	
lining	epithelium.	Particularly,	Notch3	activation	was	 increased,	and	 in vitro	 inhibition	of	
Notch	resulted	in	reduced	proliferation	and	cyst	formation	in	3D	culture	of	primary	human	
ADPKD	 cells82.	 Thus,	 modulation	 of	 Notch	 signalling	 may	 be	 an	 interesting	 therapeutic	










migration	 and	 polarity,	 thereby	 contributing	 to	 organ	 homeostasis.	 They	 are	 normally	
classified	in	canonical,	which	involves	activation	and	nuclear	translocation	of	β-catenin,	and	
noncanonical,	 which	 is	 β-catenin-independent	 and	 includes	 the	Wnt/planar	 cell	 polarity	
(PCP)	 route.	 In	 kidney	 morphogenesis,	 Wnt	 orchestrates	 the	 mesenchyme-to-epithelial	
transition	necessary	for	nephrogenesis147.	The	involvement	of	aberrantly	activated	canonical	
Wnt	 pathway	 with	 renal	 fibrosis	 has	 been	 extensively	 shown	 in	 different	 injury	 animal	
model,	as	reviewed	elsewhere148.
3.4.2.2 PKD
In	 the	 context	 of	 ADPKD,	 transgenic	 mice	 with	 increased	 β-catenin	 activation	 present	
with	 renal	 cyst	development149-151.	Moreover,	 PC1	 interacts	with	β-catenin	 at	 the	plasma	





of	 c-Myc	 in	 renal	 epithelial	 cells	mimicked	 human	 ADPKD,	 and	 both	 direct	 and	 indirect	
inhibition	 of	 c-Myc	 in vivo	 resulted	 in	 amelioration	of	 the	 cystic	 phenotype,	 placing	 this	












3.4.3 Hh signalling pathway
3.4.3.1 Renal injury
The	 Hh	 signalling	 pathway	 controls	 embryonic	 development	 and	 tissue	 homeostasis.	
Deregulation	 of	 this	 pathway	 during	 kidney	 morphogenesis	 is	 associated	 with	 severe	










signalling.	 Mutations	 in	 ciliary	 genes	 lead	 to	 cystic	 renal	 disease,	 but	 also	 aberrant	 Hh	
signalling159-161.	Also,	the	loss	of	a	functional	component	of	the	Hh	pathway,	Glis2,	resulted	
in	 the	 development	 of	 nephronophthisis	 in	 human	 and	 mice162.	 In	 the	 context	 of	 PKD,	
downregulation	of	Hh	signalling	is	accompanied	by	reduced	proliferation	and	cyst	formation	
in Pkd1	mutant	mice	and	human	primary	ADPKD	cell	cultures163,164.	However,	a	recent	study	
using	 a	 conditional	 mouse	 model	 lacking	 Pkd1	 in	 combination	 with	 three	 Hh	 signalling	
members	 (Smo, Gli2 and Gli3)	 demonstrated	 that	 Hh	 pathway	 is	 not	 required	 for	 cyst	
formation	in	mouse	models	of	developmental	or	adult-onset	of	ADPKD165.	Thus,	 it	seems	
that	 the	Hh	pathway	does	not	have	a	causative	 role	 for	 the	disease	 in vivo,	but	 it	might	
contribute	to	disease	progression	due	to	its	effect	on	renal	fibrosis.
3.4.4 Hippo signalling pathway
3.4.4.1 Renal injury
The	 Hippo	 pathway	 regulates	 tissue	 growth	 and	 development.	 Unlike	 the	 pathways	
mentioned	 above,	 which	 are	 activated	 by	 the	 binding	 of	 specific	 ligands,	 a	 diversity	 of	




responsible	 for	 the	 phosphorylation	 of	 the	 final	 effectors	 Yes-associated	 protein	 (YAP)	
and	transcriptional	coactivator	with	PDZ-binding	motif	(TAZ).	When	the	Hippo	pathway	is	







nephrogenesis	but	results	 in	renal	cyst	 formation.	This	 indicates	that	these	two	proteins,	













which	ADPKD	and	nephronophthisis129,173.	Moreover,	zebrafish	mutant	for	Pkd2 and Scrib, 
a	member	 of	 the	 SCRIB	 complex	 involved	 in	 the	 establishment	 and	maintenance	 of	 cell	
polarity,	 showed	 increased	 nuclear	 YAP.	 Interestingly,	 expression	 of	 cytoplasmic	 but	 not	
nuclear	 YAP	 could	 rescue	 the	 phenotype,	 suggesting	 that	 cytoplasmic	 YAP	 has	 a	 role	 in	
the	suppression	of	cyst	formation174.	Knock-out	of	Yap in a Pkd1	mutant	mouse	model	was	
able	to	reduce	PKD	progression	mildly,	and	the	effect	was	even	increased	by	concomitant	
knock-out	of	Taz.	In	particular,	YAP	target,	c-MYC,	was	found	to	critically	contribute	to	kidney	
cystogenesis,	 implicating	 the	Hippo	pathway	 in	 the	pathogenesis	of	 PKD175.	 Interestingly,	






of	YAP-specific	antisense	oligonucleotides	 (ASOs)	 in	adult	Pkd1 mutant mouse model did 
not	result	in	a	reduction	of	cyst	growth	(data	presented	in	chapter	3).	Such	results,	together	
with	the	cystic	effect	of	TAZ	deletion	 in	a	developmental	mouse	model,	suggest	 that	 the	
role	of	these	proteins	and	the	effect	of	targeting	them	in	PKD	is	complex	and	need	further	
characterisation171.
3.5 Transcription factors (TFs) and epigenetics in renal injury and PKD
Injury-repair	 is	 a	 complex	 mechanism	 that	 involves	 several	 cell	 types	 and	 requires	 the	
modulation	of	a	plethora	of	signalling	pathways.	Thus,	a	perfect	time-	and	space-regulated	
transcription	program	 is	paramount	 for	 the	good	outcome	of	 the	tissue	 injury	 response.	
















delaying	cyst	growth	and	preserving	renal	function	in	several	Pkd1/2 mutant mouse models, 









decline.	 Further	 investigations	 are	 required	 to	 be	 able	 to	 separate	 a	 direct	 effect	 of	 the	
polycystins	on	the	cyst	initiating	dysfunctional	molecular	mechanisms,	from	the	secondary	
effects	of	disease	progression	and	cyst	expansion.























chapter	3	we	hypothesise	 that	 reducing	YAP	 level	 in	Pkd1	KO	mice	might	ameliorate	 the	
cystic	 phenotype.	We	decided	 to	 take	 an	 approach	 based	 on	 antisense	 oligonucleotides	
(ASO)	that	target	specifically	YAP	transcripts	leading	to	a	significant	reduction	of	expression	
in	the	kidneys.	We	found	no	effect	on	cyst	progression.	We	also	investigated	the	effect	of	
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injury	using	 the	nephrotoxic	 compound	1,2-dichlorovinyl-cysteine	 (DCVC).	We	 confirmed	
that	 nephrotoxic	 injury	 can	 accelerate	 cyst	 formation	 in	Pkd1	mutant	mice.	 This	 caused	
Pkd1	 KO	mice	 to	 reach	 ESRD	 significantly	 faster;	 unexpectedly,	 double	 KO	mice	 survived	
significantly	longer.	Indeed,	cyst	formation	was	comparable	in	both	models,	but	we	found	
significantly	 lower	fibrosis	and	macrophage	infiltrates	 in	double	KO	mice.	Taken	together,	
these data suggest that Fjx1	disruption	protects	the	cystic	kidneys	against	kidney	failure	by	
reducing	inflammation	and	fibrosis.	Moreover,	we	describe,	for	the	first	time,	an	interesting	
(yet	unidentified)	mechanism	that	partially	discriminates	cyst	growth	from	fibrogenesis.











Recently,	 our	 group	 showed	 that	 a	 substantial	 proportion	of	 genes	 typically	 deregulated	
in	ADPKD	also	plays	a	role	 in	 injury-repair	mechanisms6.	 Indeed,	 less	 than	a	decade	ago,	
injury	has	emerged	as	an	important	player	in	cyst	formation	and	progression,	and	now	it	
is	 considered	a	 “modifier”	of	ADPKD7.	 Several	 other	 groups	and	we	described	 that	both	
nephrotoxic8	and	ischemic	injury,	as	well	as	unilateral	nephrectomy9-12,	were	able	to	speed	
up	 cyst	 formation	and	progression,	 reinforcing	 the	 link	between	ADPKD	progression	and	
injury.	 In	 particular,	 we	 identified	 one	 gene,	 Four-jointed box1	 (Fjx1),	 as	 an	 interesting	
player	in	these	processes.	 In	our	study,	Fjx1	showed	aberrant	expression	during	both	the	
injury-repair	phase	and	cyst	progression	in	Pkd1	KO	mice	compared	with	wild-type	mice8.	





Frizzled	signals10-12.	Fj mutant Drosophila	models	have	a	clear	alteration	of	PCP,	while	Fjx1 
KO	mice	do	not	show	any	evident	morphological	defects	in	the	kidneys	or	other	organs13,14.	
However,	deleting	 the	 target	of	FJX1,	Fat4,	 leads	 to	 loss	of	PCP	 in	 the	 inner	ear,	 cochlea	
and	the	neural	tube,	and	mild	cyst	formation	in	mouse	kidney.	Loss	of	both,	Fat4 and Fjx1, 
slightly	aggravates	the	phenotype	suggesting	that	FJX1	may	also	act	via	Fat4-independent	
pathways.	Yet,	the	effect	of	Fjx1 in a Pkd1	mutant	context	is	to	date	unknown14.	
In Drosophila,	Fj	is	also	an	upstream	regulator	of	the	Hippo	pathway,	through	its	downstream	
target	 Ft.	 The	Hippo	pathway	 regulates	 proliferation	 and	tissue	 size	 through	 the	 activity	
of	the	final	effector	and	transcriptional	co-activator	Yorki	(Yki)15-16.	 In	mammals,	there	are	
two	 Yki orthologs: Yes-associated protein 1	 (Yap1)	 and	 transcriptional coactivator with 
PDZ-binding motif	 (Wwtr1 or Taz).	When	 the	Hippo	pathway	 is	active,	YAP1	and	TAZ	are	
phosphorylated	and	retained	in	the	cytoplasm,	preventing	their	nuclear	translocation	and	







































was	 isolated	using	Tri-Reagent	 (Sigma-Aldrich).	 cDNA	 synthesis	was	performed	using	 the	
Transcriptor	First	Strand	cDNA	Synthesis	Kit	(Roche),	and	qPCR	was	done	using	2×	FastStart	









Mice double KO for Pkd1 and Fjx1 survive longer after toxic tubular damage compared 
with mice single KO for Pkd1. 
Inactivation	of	 the	Pkd1	 gene	was	 achieved	by	oral	 administration	of	 tamoxifen	 in	 adult	
mice.	This	type	of	mouse	model	is	characterized	by	a	relatively	slow	cyst	growth	that	allows	
having	reasonable	time	windows	for	the	study	of	the	different	steps	of	disease	progression.
We	 showed	previously	 that	 upon	nephrotoxic	 injury	 cyst	 initiation	 is	 faster	 in	mice	with	
Pkd1	 deletion	 compared	with	 the	 non-injured	 group8.	 Using	 the	 same	 injury	model,	we	





Figure 1. Blood Urea Nitrogen (BUN) level after DCVC 
injection and during disease progression 







after	DCVC	 injection.	 All	 the	 genotypes	 are	 back	 to	 normal	
level	after	a	week	post	injury	induction.	(C) BUN level in Pkd1 







later than Pkd1	 KO	 +	 DCVC	 (Two-way	 ANOVA	 with	 Tukey’s	
multiple	comparisons	test,	P	value	<0.05).	(E)	Representative	
whole-mount	 kidneys	 at	 renal	 failure	 (Pkd1	 KO	 and	 double	
KO)	or	24	weeks	after	DCVC	(Wt	and	Fjx1	KO).	Pkd1	KO	and	
double	 KO	 kidneys	 show	 enlarged	 cystic	 kidneys,	 opposite	









after	 injury.	 This	 was	 significantly	 earlier	 than	 in	 the	 vehicle	 group,	 which	 survived	 for	
about	19	weeks,	 in	accordance	with	previously	generated	data	 (Figure	1C)8.	 Surprisingly,	
we	observed	that	the	double	KO	mice	did	not	show	a	difference	between	DCVC	and	vehicle	
treatment	 with	 a	 median	 survival	 of	 20	 and	 21	 weeks,	 respectively	 (Figure	 1D).	 When	




Knocking-out Fjx1 in Pkd1 mutant mice does not affect cyst formation
Since	renal	injury	accelerates	cyst	formation	in	Pkd1	KO	mice8,21-24,	we	wondered	whether	




difference	 in	 the	 cystic	 index,	 and	 two	 kidneys	weight	 to	 body	weight	 (2KW/BW)	 ratio’s	
between	the	genotypes	at	this	time	point	(Figure	2A-C).	Thus,	the	initiation	of	cyst	formation	
is	not	different	in	the	two	models,	suggesting	a	role	in	cyst	growth.	


















Chronic injury caused by cyst formation leads to differences in injury markers expression, 
fibrosis and inflammatory responses in double KO compared with Pkd1 KO mice
Cyst	 formation	 is	 accompanied	 by	 inflammation	 and	 fibrosis	 which	 ultimately	 leads	 to	
complete	 loss	of	 renal	 function.	As	 changes	 in	 these	processes	might	 affect	 survival,	we	







induced	 chronic	 injury	 (Figure	 4A).	 Interestingly,	 at	 kidney	 failure,	 Kim1 expression	 was	
significantly	higher	in	Pkd1	KO	mice	compared	to	double	KO	(Figure	4B).
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Figure 4. Expression of genes involved in injury-repair in Pkd1 KO and double KO mice 
(A)	 Gene	 expression	of	Kim1	 (Havcr1)	 at	 10	weeks	 after	DCVC	 injection.	 Both	Pkd1	 KO	 and	double	 KO	have	 a	
significant	increase	of	Kim1	expression	compared	to	the	PBS	groups	and	the	Wt	and	Fjx1	KO	with	and	without	injury	
(significance	not	shown	on	graph),	but	not	compared	to	each	other.	(B)	Gene	expression	of	Kim1	at	kidney	failure	
after	DCVC	 injection	 (significance	to	Wt	and	Fjx1	KO	not	shown	on	graph).	 (C)	Gene	expression	of	Col1a1, Vim 
and Fn1	at	10	weeks	after	DCVC	injection.	(D)	Gene	expression	of	Col1a1, Vim and Fn1	at	kidney	failure.	(E) Gene	


























results	 indicate	 that	 the	 lack	 of	 Fjx1	 leads	 to	 a	 reduced	 inflammatory/fibrotic	 response	
which	translates	into	a	longer	survival	after	DCVC	administration.









Mice double KO for Pkd1 and Fjx1 show less sensitivity to DCVC induced injury than mice 
single KO for Pkd1
To	 further	 investigate	 the	 role	 of	 FJX1	 in	 injury,	 we	 performed	 a	 pilot	 experiment	 in	
which	mice	 treated	with	DCVC	were	 sacrificed	after	24	h,	48	h	and	72	h,	 i.e.	during	 the	
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PCP is altered in Pkd1 mutant mice after injury but is not significantly affected by the lack 
of Fjx1
Tissue	 injury	causes	 inversion	or	 loss	of	PCP	 in	epithelial	cells,	which	recovers	during	the	




The	levels	of	expression	of	Fat4 and its ligand Dchs143	were	unchanged	by	Fjx1	KO	(Figure	6C)	
suggesting	that,	at	the	expression	level,	the	Fat/Ds	PCP	pathway	was	unaltered	in	kidneys	of	
mutant	mice.	We	also	used	the	Golgi	position	to	assess	the	degree	of	polarity	perturbation	
in	 tubular	 cells	 (Figure	6D).	Although	Golgi	 position	 is	 not	 a	direct	 read-out	of	 PCP	 core	
proteins,	it	is	found	to	be	aberrant	when	PCP	genes	are	knocked-out44, and is also associated 
with	loss	of	directed	secretion,	cell	polarity	and	wound	healing	capacity45.	











increased	 nuclear	 localization	 of	 Yap	 in	 the	 cystic	 epithelium17.	 However,	 we	 could	 not	
detect	 any	 significant	 difference	 between	 double	 KO	 and	 Pkd1	 KO.	 Also,	 neither	mRNA	
levels	of	Yap1	 and	 its	paralog	Taz,	nor	 their	 transcriptional	 targets,	Amotl2, Cyr61, Wtip, 
Ctgf, Ajuba	(Supplementary	Figure	6),	showed	any	significant	difference	among	genotypes.	
FOUR-JOINTED KNOCK-OUT DELAYS RENAL FAILURE IN AN ADPKD MODEL WITH KIDNEY INJURY 
53
2
Figure 6. Expression of Wnt pathway target genes and expression level of Fjx1 targets and Golgi position in 
tubular cells 
































a	result,	the	mice	lacking	both,	Fjx1 and Pkd1,	have	less	fibrosis,	which	 leads	to	a	slower	
progression	to	ESRD	and	longer	survival.	
Fj	is,	together	with	the	Ft-Ds	cassette,	part	of	a	signalling	complex,	which	is	involved	in	the	







knocking-out	 Fat4,	 a	 target	 of	 FJX1,	 suggesting	 a	more	 indirect	 effect	 of	 FJX1	 on	 PCP	 in	
mammals14,19.	We	already	showed	in	a	previous	study	that	PCP	is	impaired	in	Pkd1	KO	mice	












with	 cyst	 formation.	We	 showed	 in	 the	 past	 that	 Yap1	 accumulates	 in	 the	 nuclei	 of	 the	
cyst-lining	 epithelium8,17,	 and	 other	 groups	 showed	 how	 deregulations	 of	 YAP1	 activity	
CHAPTER 2
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could	 induce	cyst	 formation	 in	Zebrafish	models57,58.	Moreover,	 knocking-out	Taz in mice 
leads	to	glomerular	and	proximal	tubular	cyst	formation59-61.	Nevertheless,	we	did	not	see	
an	 effect	of	 FJX1	on	 the	Hippo	pathway	when	 comparing	Pkd1	 KO	and	double	 KO	mice.	
Yap1 and Taz	levels,	as	well	as	the	levels	of	several	of	their	target	genes,	were	comparable	




the	 normal	 tubular	 structure	 and	 also	 interfere	 with	 the	 extracellular	 compartment.	
This	 is	 accompanied	 by	 the	 expression	 of	 injury	markers	 and	 activation	 of	 transcription	










related	pathways,	 such	as	Notch,	Hedgehog,	hypoxia	and	Egfr	 signalling,	while	we	 found	
a	 significant	 reduction	 of	 expression	 of	Pdgfb, Tgfb1, Jak2 and Stat1,	 and	Wnt	 pathway	
target	genes	in	double	KO	compared	to	Pkd1	KO	mice.	Considering	the	well	described	role	
of	Tgfb	and	Wnt	pathways	 in	renal	fibrosis32,33,67,68,	 it	 is	plausible	 to	think	that	 they	might	
be	 responsible	 for	 the	 reduced	 fibrosis	 observed	 in	 double	 KO	 mice.	 Indeed,	 Tgfb	 can	
regulate	the	expression	of	Pdgfb69, Fn1	and	type	I	collagen70,71	all	found	downregulated	in	
double	KO	mice.	Similarly,	Wnt	targets	Axin272, Cd4473, Ccnd174,75 and Myc76	were	lower	in	
double	KO	mice.	Further	studies	are	required	to	link	FJX1	with	the	Tgfb	and	Wnt	pathways	
mechanistically.	An	interesting	connection	between	FJX1	and	Jak/Stat	pathways	has	been	
described	 in	 the	 literature,	with	 Fj	 as	 the	effector	of	 the	pleiotropic	pathway	 Jak/Stat	 in	
Drosophila10.	Although	it	is	tempting	to	speculate	that	this	might	be	the	route	through	which	












As	 the	 function	 of	 FJX1	 is	 still	 obscure,	 we	 cannot	 exclude	 that,	 besides	 the	 canonical	
targets	Fat	and	Dachsous,	additional	direct	targets	of	FJX1	exist.	This	 is	because	FJX1	 is	a	
Golgi	secretory	pathway	kinase	and	therefore	likely	involved	in	many	biological	processes,	
as	 already	 shown	 for	 its	 closely	 related	 homolog	 Fam20C78,79.	 Additionally,	 FJX1	 protein	
undergoes	partial	proteolytic	cleavage	at	the	N-terminus,	with	the	secretion	of	the	resultant	
fragment	 that	can	 function	as	signalling	 ligand,	 influencing	surrounding	cells.	FJX1	 fusion	
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Supplementary Figure 1. Correlation of fibrosis and kidney size in Pkd1 KO and Pkd1/Fjx1 double KO mice 
Linear	regression	of	2KW/BW	ratio	and	gene	expression	normalized	on	Hprt	of	Col1a1, Vim and Fn1	at	10	weeks	
time	point.	**	P	value	<0.01
Supplementary Figure 2. Expression of pSTAT3 in Pkd1 KO and double KO mice 
(A)	Representative	immunostaining	for	pSTAT3	at	10	weeks	after	injection	of	the	nephrotoxic	compound	S-(1,2-





Supplementary Figure 3. Investigation of pathways involved in renal fibrosis at 10 weeks after injection of the 
nephrotoxic compound S-(1,2-dichlorovinyl)-L-cysteine (DCVC) 
Gene	expression	in	Pkd1	KO	mice	and	Pkd1/Fjx1	double	KO	mice	with	or	without	renal	injury	induced	via	injection	
of	DCVC,	of	Notch	target	genes	(Notch1, Notch2, Notch3);	Hedgehog	target	genes	(Hes1, Hey1, Gli2);	Egf	pathway	
(Hb-egf, Egfr);	hypoxia	pathway	(Hif1a, Vegfa, Pdgfb).	Each	symbol	shows	data	from	one	mouse.	Mean	±	SD.	Two-
way	ANOVA	with	Tukey’s	multiple	comparisons	test.	*	P	value	<0.05;	**	P	value	<0.01.
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Supplementary Figure 5. Injury and fibrotic genes expression at early time points after injury 




Supplementary Figure 6. Hippo Pathway activation in Pkd1 KO and Pkd1/Fjx1 double KO mice 
(A)	Representative	immunostaining	for	Yap1	on	kidney	tissue	in	Pkd1	KO	mice	after	injection	of	the	nephrotoxic	
compound	 S-(1,2-dichlorovinyl)-L-cysteine	 (DCVC)	 and	 (B)	 double	 KO	mice	 after	DCVC.	 In	 both	 genotypes,	 it	 is	
possible	 to	observe	 some	dilated	 tubules	which	 intensely	 stain	 for	 Yap1	and	diffuse	nuclear	 localization.	 Scale	
bars,	100	μm.	Arrows	indicate	tubules	showing	nuclear	Yap1;	asterisks	indicate	dilated	tubules.	(C) Yap1 and Taz 
expression	during	disease	progression.	(D)	Gene	expression	of	representative	Yap1/Taz	targets.	Each	point	is	the	
mean	expression	of	six	mice	±	SD.






described	previously1.	The	Fjx1-/-	 (Fjx1	KO)	were	generated	via	 insertion	of	the	LacZ gene 














Blood	urea	nitrogen	 (BUN)	 level	assessment	has	been	described	previously3.	At	 sacrifice,	
mice	were	weighed;	then	kidneys	were	collected	and	weighed	to	calculate	the	2	kidneys	
weight	to	body	weight	ratios	(2KW/BW).
IHC, Golgi position, Cystic and Fibrotic indices
Formalin-fixed	 paraffin-embedded	 kidneys	 were	 sectioned	 at	 4µm	 thickness.	 Section	
stained	with	Periodic	acid-Schiff	(PAS)	staining	were	used	to	determine	cystic	index	(CI).	CI	is	
measured	as	the	ratio	of	cystic	area	over	the	total	parenchyma	area	using	Image	J	software	





















For	 the	evaluation	of	 the	Golgi	position	as	a	read-out	of	 the	PCP	we	used	a	mouse	anti-
GM130	 followed	 by	 a	 secondary	 Alexa	 488	 Goat	 Anti-mouse	 IgG1	 and	 mounted	 with	
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The	 final	 effectors	 of	 this	 pathway	 are	 two	 transcriptional	 co-activators,	 Yes-associated	
protein	 (YAP)	 and	 Transcriptional	 co-activator	 with	 PDZ-binding	 motif	 (WWTR1	 or	 TAZ).	
Previously,	we	showed	aberrant	activation	of	the	Hippo	pathway	in	Autosomal	Dominant	
Polycystic	 Kidney	Disease	 (ADPKD),	 suggesting	 that	 YAP/TAZ	might	 play	 a	 role	 in	 disease	
progression.	 Using	 Antisense	Oligonucleotides	 (ASOs)	 in	 a	mouse	model	 for	 ADPKD,	we	
efficiently	downregulated	Yap	levels	in	the	kidneys.	However,	we	did	not	see	any	effect	on	
cyst	formation	or	growth.	Moreover,	the	expression	of	YAP/TAZ	downstream	targets	was	not	
changed,	while WNT	and	TGF-β	pathways	downstream	targets Myc, Acta2 and Vim,	were	
more	expressed	after	Yap	knock-down.	Differences	 in	YAP/TAZ	expression	pattern	 in vivo, 
as	well	as	 in vitro	experiments	using	Yap or Taz	mutant	 renal	cells,	 suggest	 that	YAP/TAZ	
might	play	cell-type-specific	roles	in	kidneys.	In vitro	experiments	revealed	that	knock-out	
of	Yap	is	associated	with	cytoskeleton	changes	and	aberrant	expression	of	Itga1 and Itgav.	
Although	highly	impaired,	cyst	formation	and	swelling	were	not	prevented	by	Yap nor Taz 
knock-out	in vitro	indicating	that	YAP	levels	reduction	is	not	a	viable	strategy	to	modulate	
PKD	progression.







the	 kinase	 Hippo,	 which	 has	 two	 homologues	 in	 mammals:	 mammalian	 sterile	 20-like	
protein	kinases	1	and	2	(MST1/2).	MST1/2	together	with	large	tumour	suppressors	1	and	
2	(LATS1/2)	can	phosphorylate	the	pathway	effectors	Yes-associated	protein	(YAP)	and	its	
paralogue	Transcriptional	 co-activator	with	PDZ-binding	motif	 (WWTR1	or	TAZ),	 resulting	
in	their	retention	into	the	cytoplasm.	When	the	Hippo	pathway	is	inactive,	YAP	and	TAZ	are	
unphosphorylated	and	can	shuttle	to	the	nucleus	where	they	can	work	as	transcriptional	
co-activators	driving	 the	 transcription	of	 genes	 involved	 in	proliferation	and	apoptosis1,2.	
Indeed,	 elevated	 YAP/TAZ	 protein	 levels	 and	 nuclear	 localisation	 have	 been	 observed	 in	
multiple	human	cancers1,3-6.	
In	a	previous	study,	we	showed	altered	Hippo	signalling	in	Autosomal	Dominant	Polycystic	
Kidney	Disease	 (ADPKD)7.	 ADPKD	 is	 characterised	 by	 progressive	 deterioration	of	 kidney	





of	 the	YAP	 transcriptional	 targets	Birc-3, Ctgf, Inhba and Fjx1.	 This	was	 further	observed	















Wild-type	 (Wt)	 mouse	 inner	 medulla	 collecting	 duct	 cells	 from	 ATCC	 (mIMCD3,	 CRL-
2123™	ATCC®,	 City	 of	Manassas,	 VA,	USA)	 and	Madin-Darby	 canine	 kidney	 (MDCK)	 cells	
(CCL-34™;	ATCC)	were	commercially	available.	Briefly,	cells	were	maintained	at	37°C,	and	
5%	 CO2	 in	 DMEM/F-12	with	 GlutaMAX	 (#31331-093;	 Gibco,	 Life	 Technologies,	 Carlsbad,	






were	 cultured	 in	 normal	 condition	 for	 72	 h	 and	 subsequently	 stimulated	 with	 forskolin	
(#344270,	Calbiochem,	Millipore	B.V.,	Amsterdam,	NH,	The	Netherlands)	or	DMSO	for	72	h.	
Cells	were	collected	for	immunohistochemistry	(IHC)	or	RNA	extraction.
Generation of knock-out cell lines
Generation	 of	 the	 Pkd1	 knock-out	 cell	 line	 mIMRFNPKD5E4	 was	 described	 before23	 by	
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cloned	 into	a	vector	containing	a	hygromycin	selection	gene,	 to	 facilitate	 the	deletion	of	
exon	3	Yap1 gene in the Pkd1	knock-out	cell	line	mIMRFNPKD5E4.	After	co-transfection	with	
eSpCasCsy	and	hygromycin	 selection	 (0.1	mg/ml),	approximately	75	 single	 colonies	were	
analysed:	2	clones	had	deletions	on	both	Yap1	alleles	and	were	verified	using	RT-PCR	and	
sequencing.	For	detailed	protocols,	see	Supplementary	Methods.




Inducible	 kidney-specific	 Pkd1	 deletion	 mice	 (iKspPkd1del)	 and	 tamoxifen	 administration	
have	been	described	before25.	Pkd1	gene	has	been	knocked-out	at	post-natal	day	18	(PN18).	
32	male	mice	have	been	divided	 into	 two	experimental	 groups	of	 16	 animals	 each:	 one	
received	scrambled	antisense	oligonucleotide	(ASO),	the	other	received	Yap-specific	ASO.	
Both	groups	received	an	injection	of	100	mg/kg	of	ASO	via	i.p.	injection,	starting	two	weeks	
after	Pkd1	 inactivation	 (PN18	+	2	weeks),	once	a	week,	until	 sacrifice	 (PN18	+	8	weeks).	
ASOs	 were	 provided	 by	 IONIS	 Pharmaceuticals	 (Carlsbad,	 CA,	 USA).	 Both	 ASOs	 were	
16mer	S-constrained	ethyl	gapmers	with	a	3-10-3	chimeric	design	and	a	phosphorothioate	
backbone.	Yap	ASO	sequence	was:	5’-AACCAACTATTACTTC-3’;	scrambled	ASO	sequence	was:	






Immunofluorescence, Immunohistochemistry and Western blotting
Cells	 were	 grown	 on	 coverslips	 and	 fixed	 in	 4%	 paraformaldehyde	 for	 15	min,	 at	 room	
temperature.	 Then,	 cells	 were	 permeabilised	 in	 0.2%	 Triton-X100	 in	 PBS	 for	 10	min,	 at	
room	temperature.	Cells	were	blocked	in	5%	non-fat	dried	milk	in	PBS	for	1	hour	and	then	
incubated	with	Phalloidin	Atto	594	(1:1500)	in	2%	BSA	in	PBS.	Immunofluorescence	slides	
were	 mounted	 with	 Vectashield	 containing	 DAPI	 and	 pictures	 were	 taken	 on	 the	 Leica	
DM5500	B	microscope.













#926-32211;	 LI-COR	 Biosciences;	 Lincoln,	 NE,	 USA)	 and	 goat-anti-mouse	 IRDye	 680RD	
(1:10000;	#926-32220;	LI-COR	Biosciences).	
Quantification of Ki-67 positive cells
Formalin-fixed	paraffin-embedded	kidneys	were	sectioned	at	4	µm	thickness	and	stained	
overnight	 at	 room	 temperature	with	 rabbit	 anti-Ki-67	 antibody	 and	 counterstained	with	
haematoxylin.	Sections	were	acquired	using	Philips	Ultra	Fast	Scanner	at	20x	magnification	











manufacturer’s	 protocol.	 Data	were	 analysed	with	 LightCycler	 480	 Software,	 Version	 1.5	
(Roche).	Gene	expression	was	normalised	to	the	housekeeping	gene	Hprt or GAPDH.	For	
primer	sequences	see	Supplementary	Table	1.

























tumour-like	mass.	Stimulation	with	 forskolin	did	not	 result	 in	 swelling	of	 the	 tumour-like	
agglomerates.	Only	the	sporadic	cysts	that	already	had	developed	a	lumen	before	forskolin	
treatment,	 increased	 in	size.	These	data	 indicate	 that	cyst	growth	per	se	 is	not	 impaired	
(Figure	1a),	suggesting	that	Yap	KO	impairs	cyst	formation,	but	not	growth,	in vitro.
mIMCD3 cells double knock-out for Yap and Pkd1 do not form cysts in vitro
We	are	 interested	 in	 the	 role	 of	 YAP	 in	 the	 context	 of	 ADPKD.	 Therefore,	we	 generated	






















Nevertheless,	 the	 relative	 increase	 in	 the	 size	of	TAZ	 KO	cysts	upon	 forskolin	 stimulation	
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was	comparable	 to	 that	observed	 in	Wt	 (Figure	1c).	Thus,	TAZ KO	does	not	prevent	 cyst	
formation	and	growth	in vitro,	and	we	found	a	cell-type	difference	in	TAZ dependency.
Figure 1. 3D cyst assay using Wt and mutant cells 
(a)	 Light	microscopy	 of	mIMCD3	Wt	 and	mutant	 cells	 before	 and	 after	 forskolin	 stimulation	 (respectively	 -FSK	
and	+FSK).	H&E	staining	of	formalin-fixed,	paraffin-embedded	cysts	grown	in	Matrigel	after	forskolin	stimulation	
(bottom	 row).	 (b)	 Light	microscopy	 of	MDCK	Wt	 and	mutant	 cells	 before	 and	 after	 forskolin	 stimulation.	H&E	






















Figure 2. Immunostaining of Wt and mutant cells in 
forskolin-treated 3D cysts 
(a)	 Representative	 IHC	 of	 formalin-fixed,	 paraffin-
embedded	cysts	of	forskolin-treated	Wt	and	mutant	
mIMCD3 cells and (b) forskolin-treated	 Wt	 and	




localisation	 of	 the	 proteins;	 black	 arrowheads	
indicate	 nuclear	 localisation	 of	 the	 proteins.	 Scale	
bar	50	µm.
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YAP knock-down using ASOs does not improve cystic phenotype in vivo
We	showed	in	the	past	that	cyst-lining	epithelia	have	intense	nuclear	YAP	localisation,	both	
in Pkd1-mutant	mouse	models	and	 in	ADPKD	patients7.	Therefore,	we	hypothesised	 that	







The Yap	 ASO	 treatment	 resulted	 in	 about	 70%	 reduction	 of	 Yap	 gene	 expression	 levels	












and Amotl227.	Despite	the	consistent	Yap	 reduction	at	the	mRNA	level,	 the	expression	of	
target genes is not changed in Yap	ASO	treated	compared	to	scrambled	ASO	treated	mice	
(Figure	4d).	Additionally,	we	evaluated	the	expression	of	Ki-67,	a	marker	for	cell	proliferation,	
as	YAP	and	TAZ	can	regulate	transcriptional	programs	that	control	cell	proliferation27.	The	
Ki-67	positive	 areas	 in	Yap	 ASO	 treated	mice	were	not	 significantly	 different	 from	 those	
observed	in	scrambled	ASO	treated	mice	(Figure	4e,	f).	In	conclusion,	the	knockdown	of	Yap 
does	not	affect	the	expression	of	the	downstream	targets	we	tested.
WNT and TGF-β pathways seem to be more active in Yap ASO mice 
It	 is	well	 known	 that	both	YAP	and	TAZ	 can	 interact	with	 the	final	 effectors	of	 the	WNT	
and	TGF-β	pathways28.	For	this	reason,	we	checked	the	expression	levels	of	several	target	
genes	regulated	by	β-catenin	 (Axin2 and Myc)	and	Smads	 (Acta2, Col1a1, Vim, Fn1, Pai1 
and Mmp2).	We	observed	 increased	Myc expression	 in	Yap	ASO	 treated	mice	compared	




and	 a	 consistent	 trend	 for	 collagen	 1	 alpha-1	 (Col1a1),	 fibronectin	 (Fn1),	 plasminogen	
activator	 inhibitor-1	 (Pai1)	 and	 matrix	 metallopeptidase	 2	 (Mmp2)	 (Figure	 5b).	 Thus,	
although	 not	 conclusive,	 these	 results	 suggest	 that	WNT	 and	 TGF-β	 pathways	are more 
active	upon	Yap	knock-down.
Figure 3. In vivo downregulation of Yap with ASOs 
(a)	Schematic	representation	of	the	in vivo	experimental	pipeline.	Pkd1	gene	inactivation	was	achieved	with	three	
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mouse.	Mean	with	 ±	 SD.	 n.s.	 (not	 significant)	 refers	 to	 all	 the	 genes	 in	 the	 graph,	 t-test.	 (e)	Quantification	 of	
Ki-67	positive	area.	Each	symbol	represents	a	mouse.	Mean	with	±	SD.	n.s.	not	significant,	t-test.	(f)	Representative	
pictures	of	renal	tissue	stained	for	Ki-67.	Scale	bar	50	µm.
Yap KO affects cytoskeleton integrity and integrins expression in vitro
Following	 up	 on	 the	 aberrant	 phenotype	 observed	 in	 Yap	 KO	 cells	 grown	 in	 Matrigel,	
we	 decided	 to	 characterise	 these	 cells	 further.	We	 stained	 the	 actin	 cytoskeleton	 using	
fluorescent	 dye-conjugated	 phalloidin,	 a	 well-known	 marker	 for	 filamentous	 actin.	 Wt	
mIMCD3	 cells	 showed	 a	 normal	 cytoskeleton	 with	 clear	 cortical	 cytoskeletal	 and	 stress	
fibres	present	throughout	the	cell	body.	Also,	TAZ	KO	cells	showed	a	normal	cytoskeleton,	
similar	to	Wt	cells.	Conversely,	Yap	KO	cells	showed	aberrant	cytoskeleton	and	rarely	stress	










Figure 5. WNT and TGF-β pathway targets in vivo, and characterisation of mutant cell lines 
(a)	Gene	expression	(fold-change)	of	WNT	pathway	targets	Axin2 and Myc	at	the	sacrifice	 in	mice	treated	with	
Yap	ASO	and	scrambled	ASO.	Each	symbol	represents	a	mouse.	Mean	with	±	SD.	**	P	<	0.01,	n.s.	not	significant,	





(d) Gene	expression	normalised	on	housekeeping	genes	(Hprt	 for	mIMCD3	cell	 lines	and	GAPDH	 for	MDCK	cell	
lines)	 of	 Integrins	 alpha-1	 and	 alpha-v.	 Cells	 are	 grown	 in	Matrigel	 and	 allowed	 to	 form	 cysts.	 Subsequently,	
forskolin	is	added	to	the	medium	(+FSK)	or	DMSO	as	control	(-FSK).	Cells	are	then	collected	for	RNA	extraction,	











Indeed,	 the	 majority	 of	 patients	 with	 ADPKD	 will	 develop	 the	 end-stage	 renal	 disease	
(ESRD),	severely	impacting	patients’	lives	and	representing	a	substantial	economic	burden	



















that TAZ	KO	did	not	result	 in	 impaired	cyst	 formation	nor	cyst	growth	 in	a	3D	cyst	assay,	
arguing	against	it.	This	is	further	supported	by	in vivo results,	since	mice	with	a	constitutive	
or	 conditional	 Taz	 KO,	 develop	 mild	 cysts	 even	 in	 the	 absence	 of	 a	 Pkd1	 mutation18,33.	













Another	 difference	with	 our	 study	 is	 that	we	did	 not	 use	 a	 genetic	 deletion	of	Yap,	 but	
we	decided	 to	use	 a	 strategy	based	on	antisense	oligonucleotides	 that	 could	potentially	
be	 translated	 to	 the	clinic.	The	use	of	ASOs	allows	 to	 reduce	YAP	 levels	consistently,	but	












YAP	 and	 TAZ	 are	 transcriptional	 co-activators	 that	 can	 modulate	 a	 variety	 of	 biological	
processes.	 They	 have	 been	 associated	 with	 fibrogenesis	 and	 epithelial-to-mesenchymal	
transition	in vivo and in vitro	via	interaction	with	both	TGF-β	and	WNT	signalling	pathways.	
Particularly,	 when	 the	 Hippo	 pathway	 is	 active,	 YAP	 and	 TAZ	 are	 phosphorylated	 and	
restrained	in	the	cytoplasm	where	they	can	interact	with	SMADs	and	β-catenin,	preventing	
their	nuclear	translocation	and	transcriptional	activity28.	In	our	study,	we	observed	increased	

















signals	 via	 cell-cell	 contacts,	 polarity	 proteins	 and	 cadherin-β-catenin	 complexes,	 focal	
adhesions,	extracellular	matrix	(ECM)	elasticity	and	cytoskeletal	tension40,	as	well	as	several	
mitogens	 like	 epidermal	 growth	 factor	 (EGF),	 lysophosphatidic	 acid	 (LPA),	 sphingosine-1	
phosphate,	insulin	and	the	protease	thrombin,	which	can	control	YAP/TAZ	localisation41-45.	
Indeed,	 we	 also	 showed	 that	 in	 Yap	 KO	mIMCD3	 cells,	 expression	 of	 Itga1 and Itgav is 
impaired	and	that	the	architecture	of	the	cytoskeleton	is	aberrant.	In	3D	cysts,	this	results	
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were	 re-plated	at	 a	density	of	 ~50	 cells	 per	 9	 cm	plate.	 In	 total	 60	 single	 colonies	were	
picked	and	analysed	using	PCR	with	primers	flanking	 the	RFN	 target	 sites.	 PCR	products	
were	digested	with	restriction-endonuclease	BpmI,	which	cuts	between	the	Yap1ex2	RFN	
target	sites.	From	7	clones	that	showed	undigested	PCR	products,	demonstrating	a	deletion	





Using	 a	 similar	 method	 we	 set	 out	 to	 make	 knock-out	 cell	 lines	 for	 Wwtr1	 (202:	
ENSMUST00000120977.1),	 by	 targeting	 exon	 2	 or	 exon	 4.	 However,	 after	 screening	 200	









isolated	 using	 G418	 selection.	 In	 none	 of	 the	 250	 clones	 analysed	 exon	 3	 deletion	was	
observed	in	three	alleles.	Sequencing	of	many	clones	revealed,	deletion	of	exon	3	in	two	




results	 we	 conclude	 that	 knocking-out	 three	 alleles	 in	mIMCD3	 leads	 to	 cell	 death.	We	








of	exon	3	Yap1 gene in the Pkd1	knock-out	cell	line	mIMRFNPKD	5E4.	After	co-transfection	
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 Supplementary Table 1. List of primer sequences used for qPCR
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Polycystic	 kidney	disease	 (PKD)	 is	 a	major	 cause	of	 end-stage	 renal	disease.	 The	disease	
mechanisms	are	not	well	understood	and	 the	pathogenesis	 toward	 renal	 failure	 remains	










Pkd1-mutant	mouse	model	 as	 well	 as	 in	 animals	 treated	with	 a	 nephrotoxic	 agent.	We	
propose	that	compounds	that	can	modulate	the	injury-repair	response	could	be	valuable	
drug	candidates	for	PKD	treatment.




Polycystic	 Kidney	 Disease	 (PKD)	 is	 a	 genetic	 disease	 of	 the	 kidney	 characterized	 by	 the	
gradual	replacement	of	normal	kidney	parenchyma	by	fluid-filled	cysts	and	fibrotic	tissue.	
Autosomal	 Dominant	 Polycystic	 Kidney	 Disease	 (ADPKD)	 is	 caused	 by	 mutations	 in	 the	
PKD1 or PKD2	gene	and	the	less	frequent	autosomal	recessive	form,	Autosomal	Recessive	














Several	 studies	 indicated	a	tissue	 injury-repair	 component	 in	 the	pathology	of	PKD16,24,70.	
Indeed,	there	are	numerous	similarities	between	PKD	and	renal	injury,	since	both	phenotypes	
are	accompanied	by	a	combination	of	processes	including	proliferation,	secretion	of	growth	
factors,	 as	well	 as	 inflammation.	Weimbs70	 proposed	 a	model	where	 Polycystin	 1	 (PC1),	
the	 protein	 encoded	by	PKD1,	 and	 primary	 cilia	 have	 a	 critical	 function	 in	 sensing	 renal	




by	 findings	 that	 ischemic	 reperfusion	 injury	 and	 also	 tubular	 cell	 hypertrophy	 following	
unilateral	nephrectomy	accelerated	PKD6,16,33,47,62.	Although	the	link	between	PKD	and	renal	
injury	seems	rather	strong,	until	now	a	thorough	comparison	between	the	two	conditions	
at	 the	molecular	 level	 has	not	been	made,	 and	 little	 is	 known	about	 the	 key	 genes	 and	
pathways	shared	between	the	two.













Experimental animals and RNA Sequencing
Pkd1 Mutant and Wild-type mice



















mRNA,	a	cDNA	synthesis	was	performed.	This	was	used	 for	 ligation	with	 the	sequencing	
adapters	and	PCR	amplification	of	the	resulting	product.	The	quality	and	yield	after	sample	
preparation	 were	measured	 with	 a	 DNA	 1000	 Lab-on-a-Chip.	 The	 expected	 broad	 peak	
between	300	and	500	bp	was	observed.	





Resulting	 reads	 were	 aligned	 to	 the	 mouse	 reference	 genome	 version	 GRCm3868 using 
Tophat225	 followed	 by	 bowtie231	 in	 the	 local	 highly	 sensitive	 mode	 (bowtie2-local-very-
sensitive-local).	After	alignment,	HTSeq-count3	 (Version	0.6.1)	was	used	to	estimate	gene	
expression	 by	 counting	 reads	 that	 were	 mapped	 to	 each	 gene	 using	 default	 options.	
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Differential	 gene	 expression	 analysis	 was	 performed	 using	 limma	 package	 with	 default	
parameters	 after	 applying	 Voom	 transformation52.	 Differentially	 expressed	 genes	 were	
selected	where	false	discovery	rate	(FDR)	is	<	0.05.	Data	were	deposited	in	ArrayExpress27 
and	given	the	following	identifier	E-MTAB-5319.
Experimental animals and Fluidigm Assay
Pkd1 Mutant, Wt and DCVC-induced mice
Wt	mice	and	iKsp-Pkd1del	mice	were	feed	with	tamoxifen	(5	mg/day,	3	consecutive	days)	in	









B.V.,	 Leiden,	 The	 Netherlands)	 using	 the	 96.96	 BioMark™	 Dynamic	 Array	 for	 Real-Time	
PCR	 (Fluidigm	 Corporation,	 San	 Francisco,	 CA,	 U.S.A),	 according	 to	 the	 manufacturer’s	
instructions.	Before	use	on	 the	BioMark	array,	 the	cDNA	was	first	 subjected	 to	14	cycles	
of	Specific	Target	Amplification	using	a	0.2X	mixture	of	all	Taqman	Gene	Expression	assays	
in	 combination	with	 the	 TaqMan	PreAmp	Master	Mix	 (Applied	Biosystems),	 followed	by	
fivefold	 dilution.	 Thermal	 cycling	 and	 real-time	 imaging	 of	 the	 BioMark	 array	was	 done	
on	 the	 BioMark	 instrument,	 using	 the	 default	 Taqman	 PCR	 protocol	 with	 an	 annealing	
temperature	 of	 60˚C	 and	 a	 total	 of	 35	 cycles	 of	 PCR.	 Ct	 values	 (cycle	 threshold	 values)	
were	extracted	using	the	BioMark	Real-Time	PCR	analysis	software	(version	3.0.2)	and	the	






Data Acquisition and Meta-Analysis
Meta-Analysis PKD Signature.
In	 addition	 to	 our	 iKsp-Pkd1del,	 public	 expression	 profiling	 experiments	 of	 PKD	 were	







from	 ADPKD	 patients.	 For	 the	 large	 phenotypic	 and	 physiological	 differences	 between	
postnatal	and	embryonic	PKD	models,	embryonic	PKD	models	were	excluded.	Asymptotic	






a	 study	 had	 different	models	 or	 phenotypes	 of	 the	 disease,	 we	 processed	 the	 samples	
independently	 when	 calculating	 the	 differentially	 expressed	 genes,	 and	 only	 included	





Public Injury Models and other Kidney Diseases.
In	addition	to	our	DCVC	treated	Wts,	we	included	six	published	studies	of	renal	ischemia.	
Study	inclusion	criteria	were	based	on	the	availability	of	treated	and	nontreated	Wts	and	
availability	 of	 data	 as	 described	 in	 the	 previous	 paragraph.	 Other	 kidney	 diseases	 were	
included	 as	 mentioned	 in	 Results.	 Differentially	 expressed	 genes	 for	 each	 study	 were	
calculated	as	described	in	the	previous	paragraph.
Literature-based Signatures
Literature-Based	 Signatures	 were	 obtained	 using	 Biosemantics	 Concept	 Profile	
technology17a,21,	 calculating	 the	 literature	 association	 scores	 between	 all	 Homo Sapiens 
genes	 with	 concept	 profiles	 and	 the	 literature	 concept	 profiles	 of	 renal	 injury	 repair	 in	








Functional	 enrichment	 analysis	 was	 performed	 against	 Molecular	 Signature	 Database	











Identification of PKD Signature 
To	 identify	a	 comprehensive	expression	 signature	of	PKD	during	disease	progression,	we	
generated	new	RNASeq-based	expression	profiles	of	 inducible,	kidney	epithelium-specific	
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Figure 1. Overview of the approach used to identify the PKD Signature and comparison to renal injury and repair, 
macrophages and other kidney diseases
The	 approach	 consisted	 of	 five	 steps.	A:	 the	 PKD	 Signature	 was	 defined	 by	 combining	 publicly	 available	 PKD	
expression	 profiling	 studies	with	 our	 in-house	 RNAseq	of	 iKsp-Pkd1del	 in	mice.	B:	 the	 Injury	 Repair	 Profile	was	
defined	by	experimental	expression	profiles	of	kidneys	with	ischemia-reperfusion	injury	(IRI)	(b1),	in-house	RNAseq	
of	kidneys	from	DCVC-treated	animals	(b2)	and	literature-based	text-mining	of	genes	associated	with	injury	terms	
in	PubMed	abstracts	 (b3).	C:	 comparing	 significantly	dysregulated	genes	 from	PKD	Signature	and	 Injury	Repair	
Profile	we	identified	the	Injury	Repair	Component	of	PKD,	which	consists	of	~35%	of	the	genes	implicated	in	PKD.	




We	 identified	 2,376	 genes	 (FDR	 <	 0.05)	 that	 clearly	 distinguished	 iKsp-Pkd1del from	Wt	
mice	(Data	Set	1,	Figure	2A).	Next,	we	compared	our	expression	profile	to	other	publicly	
available	 PKD	 expression	 studies	 (Figure	 1A).	We	 used	 stringent	 study	 inclusion	 criteria	


































Authors Organism/Sex Accession Number Datasets Included No of DEGs after HC No. of DEGs in PKD Signature 
Menezes et al.39 Mouse/M and F GSE32586 
Pkd1cko.P12 vs WT.12 40 17 
Pkd1cko.P14 vs WT.14 1,200 594 
O'Meara et al.43 Rat/M GSE33056 PCK vs SD 1,586 561 
Song et al.56 Human/NM GSE7869 
Non-cystic vs normal 280 68 
Small cysts vs normal 4,554 025,1  
Medium cysts vs normal 4,650 033,1  
Malas et al. (this study) Mouse/M  E-MTAB-5319 Pkd1cko.P40 vs WT 2,376 924 
Table 1. Expression profiling studies used in the definition of the PKD Signature
PKD,	polycystic	kidney	disease;	DEGs,	differentially	expressed	genes;	HC,	homolog	conversion;	SD,	Sprague-Dawley;	
WT,	wild	type;	M,	males;	F,	females;	NM,	not	mentioned	in	the	Methods	of	the	paper.
Validation of the PKD Signature in an independent dataset
We	validated	the	PKD	Signature	in	an	independent	dataset	that	was	published	during	the	
writing	of	this	manuscript38.	This	dataset	includes	80	mouse	samples	with	induced	deletion	
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Functional annotation of the PKD Signature
We	annotated	the	up-	and	downregulated	gene	sets	using	the	Molecular	Signature	Database	




genes	involved	in	ion	transport	(i.e. CP, SLC4A1, SLC2A9, SLC12A1).
On	the	other	hand,	several	pathways	and	processes	are	upregulated	in	the	PKD	Signature	
listed	in	Data	Set	3.	We	further	grouped	the	genes	shared	between	three	or	more	studies	
into	 defined	 gene	 families	 (protein	 kinases,	 cytokines	 and	 growth	 factors,	 transcription	
factors	and	oncogenes)	to	facilitate	their	usage	in	translational	research	(Data	Set3c	and	3d).
To	 measure	 the	 relevance	 of	 the	 PKD	 Signature	 at	 the	 molecular-function	 level,	 we	
defined	four	categories	that	are	known	to	be	dysregulated	in	PKD:	cell	cycle46,	apoptosis13, 
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proliferation71	 and	 inflammatory	 response61.	 We	 found	 that	 the	 PKD	 Signature	 had	
significantly	 more	 functional	 annotations	 related	 to	 these	 categories	 than	 equally-sized	
random	sets	of	genes	pooled	from	the	genes	significant	 in	only	one	PKD	study	(binomial	
test, P	<	0.0005)	(Figure	2E).
Identification of Injury Repair genes in the PKD Signature



















Authors Organism Accession Injury Model Time after reperfusion 
Chen et al.9 Mouse GSE34351 ARI 4 h 
Correa-Costa et al.12 Mouse GSE39548 ARI 6 h 
Liu et al.35 Mouse GSE52004 ARI 24 h 
Yuen et al.73 Rat GSE3219 ARI 2, 8 h 
Krishnamoorthy et al.28 Rat GSE27274 ARI 6, 24, 120 h 
Speir et al.57 Rat GSE58438 ARI Immediate 
 






data	by	 inducing	 renal	 injury	 in	Wt	mice	using	 the	nephrotoxic	DCVC.	The	samples	were	
harvested	at	1,	2	and	5	weeks	after	injury	induction.	Measurements	of	blood	urea	showed	
that	mice	have	normal	 functional	 kidneys	at	7	days	after	 injury,	 confirming	 that	most	of	




almost	 completely	 been	 recovered	 from	 the	 injury	 (Figure	 3A).	 Comparing	 the	 different	
injury	repair	time	points	from	our	 injury-induced	model	against	each	other	we	 identified	
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rate	 (FDR)	 <	 0.05].	 On	 the	 one	 hand,	 the	 early	 injury	 repair	 genes	 had	 apoptosis,	 hypoxia	 and	 inflammatory	
response	related	pathways	in	the	most	enriched	functions	identified	from	MSigDB	and,	on	the	second	hand,	the	








Literature Injury Repair Profile 
The	Literature	Injury	Repair	Profile	is	based	on	published	knowledge	of	genes	involved	in	








Injury Repair processes in PKD
To	 find	 injury	 repair	 involvement	 in	 PKD,	 we	 compared	 the	 PKD	 Signature	 with	 the	
Experimental	Injury	Repair	Profile	and	the	Literature	Injury	Repair	Profile	(Figure	1C).	Our	







22	 terms	were	 found	 to	be	more	enriched	 in	 the	 injury	 repair	 genes	and	only	1	 term	 is	
more	enriched	in	the	non-injury	repair	genes	when	compared	with	each	other	(Figure	3E,	
Data	 Set6).	 This	 demonstrates	 the	 cohesiveness	 of	 the	 injury	 repair	 genes.	Many	of	 the	
injury	repair	functions	are	related	to	NF-kB	signaling,	epithelial-to-mesenchymal	transition,	
inflammatory	 response,	 hypoxia,	 and	 metabolism.	 Although	 these	 functional	 terms	 are	
expected	in	a	well-defined	injury	repair	signature,	they	demonstrate	that	we	zoomed	in	on	
a	relevant	group	of	genes	(Table	3).	




Term Name Count FDR Genes (Gene Symbol) 
TNFA_SIGNALING_VIA_NFKB 43 1.9E-38 
CD44, GADD45B, RHOB, PLAUR, JUN, CYR61, CXCL1, TNC, MAFF, F3, 
KLF6, CSF1, MYC, NFIL3, PHLDA1, GCH1, CDKN1A, BTG2, HBEGF, SPHK1, 
TLR2, ICAM1, CCL2, KYNU, ETS2, PPP1R15A, BTG1, FOSL2, BIRC3, MCL1, 
PLK2, IER5, SOCS3, CXCL3, BCL3, CEBPB, JUNB, CXCL2, TGIF1, CEBPD, 
EGR1, PANX1, LITAF 
EPITHELIAL_MESENCHYMAL_TRANSITION 37 1.44E-30 
CD44, GADD45B, RHOB, PLAUR, JUN, CYR61, CXCL1, TNC, TIMP1, SPARC, 
FN1, FBN1, THBS1, SPP1, ITGA5, DCN, TGFBI, TNFRSF12A, SDC1, COL4A2, 
COL3A1, COL1A1, ITGB1, ITGB5, TAGLN, TPM2, COL1A2, LAMC2, FSTL1, 
BASP1, DPYSL3, LOXL2, MGP, PCOLCE, SFRP4, TPM4, VIM 
COAGULATION 25 3.65E-20 
TIMP1, SPARC, FN1, FBN1, THBS1, MAFF, F3, MEP1A, KLF7, ANXA1, CFH, 
MMP9, DUSP6, CAPN5, PF4, C3, CSRP1, FGA, FGG, MSRB2, CFI, APOC3, 
P2RY1, PROC, CAPN2 
INFLAMMATORY_RESPONSE 28 8.01E-20 
TIMP1, F3, MEP1A, PLAUR, ITGA5, KLF6, CSF1, MYC, GCH1, CDKN1A, 
BTG2, HBEGF, SPHK1, TLR2, ICAM1, CCL2, RGS16, TNFRSF1B, IL4R, 
TPBG, CD14, OSMR, TAPBP, BST2, RHOG, SLC7A1, PDPN, AXL 
XENOBIOTIC_METABOLISM 28 8.01E-20 
GCH1, KYNU, ETS2, GABARAPL1, AHCY, RETSAT, CROT, HSD11B1, 
ALDH9A1, TNFRSF1A, CAT, ACOX1, POR, APOE, FMO1, BPHL, PDK4, 
SLC6A12, TMBIM6, ESR1, SLC46A3, GSS, ARG2, MAN1A1, NDRG2, 
SLC12A4, NFS1, ENTPD5 
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the	disease,	 the	non-injury	repair	 is	 twice	as	enriched	 in	comparison	to	the	 injury	repair	




growth,	 epithelial-to-mesenchymal	 transition	 and	metabolism	 (Data	 Set	 7b).	 In	 addition, 
several	cytokines	that	are	associated	with	kidney	injury	are	upregulated	in	the	early	phases	
of	PKD,	such	as	osteopontin	(OPN)	and	growth	differentiation	factor	15	(GDF15).	
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Experimental validation of the injury component in independent samples
To	validate	our	results,	we	generated	an	independent	set	of	adult-onset	slow-progressing	




genes;	Inflammatory	response	(Pcdh7 and Stat3),	hypoxia	(Akap12 and Anxa2), epithelial-to-
mesenchymal	transition (Dpysl3 and Tnfrsf12a), TNF-α/NF-κB	signaling	(Socs3), coagulation	







Macrophages in Polycystic Kidney Disease
Macrophages	 have	 important	 roles	 in	 renal	 injury	 repair	 and	 PKD3,50,60.	 Having	 identified	
the	injury	repair	genes	of	the	PKD	Signature,	we	proceeded	to	identify	novel	macrophage-
related	molecular	pathways	 involved	 in	PKD	progression.	Using	data	of	Clements et al.11, 
which	contains	unique	expression	profiles	of	different	macrophage	populations	upon	renal	
injury	 induction. They	 identified	 three	 distinct	 macrophage	 populations:	 the	 "CD11b+/
Ly6Chigh"	population	associated	with	the	onset	of	renal	injury	and	increase	in	proinflammatory	
cytokines,	 the	 "CD11b+/Ly6Cintermediate"	 population	 that	 peaked	 during	 kidney	 repair,	 and	
the	"CD11b+/Ly6Clow"	population	that	emerged	with	developing	renal	fibrosis.	We	looked	
for	genes	that	are	up-regulated	in	the	PKD	Signature	and	uniquely	upregulated	in	each	of	

























Figure 5. Validation of the PKD Signature in 
an adult onset iKsp-Pkd1del model and in a 
nephrotoxic injury model 
A:	 cyst	 progression	 in	 the	 adult	 iKsp-Pkd1del 
mice.	 I-III:	 PAS	 staining	 on	 formalin	 fixed,	
paraffin	embedded	kidney	sections,	 scale	bar	
=	 100	 µm.	 Mild	 tubular	 dilation	 at	 5	 (I),	 10	




disease	was	 observed,	 with	median	 duration	
until	 kidney	 failure	 of	 19	 weeks.	 B: genes 
selected	 randomly	 from	 the	 PKD	 Signature,	
were	 subjected	 to	 qPCR	 on	 the	 iKsp-Pkd1del 
mice	model	 described	 in	A and age-matched 
Wts	at	1,	2,	5,	10	weeks	after	gene	knockout,	
and	 at	 kidney	 failure.	 Normalized	 Ct	 values	
(cycle	 threshold	 values)	 are	 plotted	 (log2	
scale)	 for	 each	 gene	 separately	 across	 five	
measurement	 time	 points	 for	 three	 types	 of	
samples:	 wild-type	 mice	 treated	 with	 saline	
(WTPBS,	 red),	 iKsp-Pkd1del mice	 treated	 with	
saline	 (Pkd1cko,	 green)	 and	 wild-type	 mice	
treated	with	DCVC	 (WTDCVC,	blue).	 For	each	
time	 point,	 the	 significance	 of	 dysregulation	
in	RNA-levels	with	respect	to	WTPBS	mice	was	
tested	using	Student’s	t-test.	Grey	bars	below	
the	 x-axis	 are	 used	 in	 case	 of	 no	 significance	
(P ≥	0.01)	and	darker	shades	of	colors	 (green	
for	PKD	and	blue	for	injury)	are	used	to	denote	






Comparison of the PKD Signature with other kidney diseases
We	compared	the	PKD	Signature	with	other	kidney	diseases,	for	which	expression	profiling	
studies	have	been	published	in	the	literature1,7,63,72	(Table	4).	The	Fh1	knockout	hereditary	
leiomyomatosis	and	renal	cell	 cancer	 (HLRCC)	model	 that	develops	 renal	cysts49, had the 
highest	enrichment	with	the	PKD	Signature	with	RF	of	3.3.	In	addition,	the	overlap	of	other	
kidney	 diseases	 such	 as	 glomerulonephritis63	 and	 diabetic	 nephropathy72,	 with	 the	 PKD	




in	 functions	 related	 to	 the	 immune	 system	 and	 epithelial-to-mesenchymal	 transition,	
suggesting,	 that	most	of	 the	overlap	of	 the	PKD	Signature	with	other	 kidney	diseases	 is	
related	 to	 injury	 repair	 and	 inflammation.	 To	 test	 this,	 we	 compared	 the	 enrichment	
of	each	disease	with	both	the	 injury	repair	genes	and	the	non-injury	repair	genes	of	 the	





diseases	and	 injury	 repair	processes	 (Figure	4D).	 Interestingly,	 the	unique	PKD	Signature	
genes,	are	the	genes	with	the	least	known	functional	annotations	(<12%	of	genes	mapped	
to	annotation	terms)	(Figure	4D).






Authors Organism Accession Disease Mouse Model 
Adam, J. et al.1 Mouse GSE10989 HLRCC Fh1 knock-out 
Braun, F et al.7 Mouse GSE3219 Aging kidney Aged wild-type mice 
Tamura K et al.63 Mouse GSE45005 Glomerulonephritis ICGN mice 
Yang et al.72 Mouse GSE20844 Diabetic nephropathy OVE26 mice 
 




In	 this	 work,	 we	 have	 created	 a	 robust	 PKD	 Signature	 that	 would	 help	 in	 the	 ongoing	
translational	research	efforts	to	find	novel	treatments	for	PKD	patients.	We	followed	a	meta-









from	 our	 PKD	 Signature.	 In	 addition,	 significant	 enrichments	 were	 observed	 in	 mild,	
moderate	and	advanced	stages	of	 the	disease,	 in	both	males	and	 females.	These	 results	











renal	 injury	 repair	 profiles.	We	 also	 contributed	 a	 new	dataset	 of	 injury	 induced	mouse	
model	that	covers	the	late-injury	repair	response	phase.	Our	results	are	in	line	with	these	
suggestions,	where	we	were	able	 to	 link	35%	(581	genes)	of	 the	PKD	Signature	genes	to	
injury	repair	 response.	This	overlap	 is	 two	times	more	enriched	than	randomly	expected	
(RF=2).	 Interestingly,	 these	 injury	 repair	 genes	 are	 involved	 in	 more	 than	 65%	 of	 the	
functional	annotations	attributed	to	PKD.	The	most	enriched	functions	of	the	PKD	signature	
injury	 repair	genes	 include	epithelial-to-mesenchymal	 transition,	proliferation,	apoptosis,	











MCM2, MCM5, PLK1 and CDKN1A),	 genes	 involved	 in	 extracellular	matrix	 development	
and	morphogenesis	 (i.e. OPN, TPM4, TGFBI and TNFRSF12A),	genes	 involved	 in	transport	
of	 cations/anions	 and	 amino	 acids/oligopeptides	 (i.e. SLC25A10, SLC38A2, SLC6A12)	 and	










evident	 in	 the	 macrophage	 populations	 "CD11b+/Ly6Cintermediate"	 and	 "CD11b+/Ly6Clow",	
























of	 the	disease	and	how	altered	 injury	repair	processes	augment	 it	over	time.	Comparing	
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Autosomal	 Dominant	 Polycystic	 Kidney	 Disease	 (ADPKD)	 is	 the	 most	 common	 genetic	
renal	disease,	caused	in	the	majority	of	the	cases	by	a	mutation	in	either	the	PKD1 or the 
PKD2	 gene.	ADPKD	 is	 characterised	by	a	progressive	 increase	 in	 the	number	and	 size	of	







TFs	with	altered	expression	 in	PKD	and	32	of	those	were	also	 implicated	 in	tissue	 injury/
































mouse models3,4.	 Recently,	 we	 showed	 that	 renal	 injury	 shares	 molecular	 processes	




Transcription	 factor	 proteins	 (TFs)	 are	 master	 regulators	 of	 transcription,	 which	 control	
the	expression	of	genes	 involved	 in	 the	establishment	and	maintenance	of	cell	 states,	 in	















studies.	 We	 further	 identified	 genes	 involved	 in	 injury/repair	 processes	 from	 the	 PKD	
Signature	by	 firstly	 producing	 Injury	Repair	 gene	profile	 based	on	 several	 injury-induced	
animal	models	 and	 secondly	 intersecting	 the	 identified	 PKD	 Signature	 and	 Injury	 Repair	
Profiles	for	the	identification	of	overlapping	genes.	















(740)	 regulated	 lists	 independently);	N	=	 total	 genes,	 in	 this	 case,	 the	10271	genes	with	
Entrez	IDs.
In silico functional annotation of gene lists
GeneTrail2	 v1.69	was	used	 to	 identify	 the	enriched/significant	pathways/functions	of	 the	
identified	 gene	 lists.	 For	 all	 analyses,	 we	 used	 Wikipathways	 as	 the	 primary	 source	 of	
annotation.	GeneTrail2	 v1.6	was	 run	with	 the	 following	parameters:	Over-representation	
analysis	(enrichment	algorithm);	FDR	adjustment	(adjustment	method);	significance	level	at	
0.05;	minimum	and	maximum	size	of	the	category	equal	to	2	and	700	respectively.











for	 Fluidigm	 data	 and	Hprt	 for	 SYBR-Green	 data. The	 output	 of	 the	 Fluidigm	 assay	was	





Identification of Transcription Factors Binding Sites and primer design
For	 the	 TFs	 that	 were	 selected	 for	 our	 ChIP	 analysis,	 we	 identified	 the	 binding	 sites	 of	
each	TF	and	its	targets	by	screening	the	Cistrome	database11 and accessing all studies that 
performed	ChIP-Seq	experiments	on	our	selected	TFs.	We	looked	for	peaks	that	appeared	
with	an	 intensity	of	10	or	higher	 in	more	than	one	ChIP-Seq	study.	We	mapped	the	Mus 
musculus	mm10	genome	to	the	peaks	identified	using	Peak2Gene tool	that	is	part	of	the	
Cistrome	Galaxy	tools	to	 identify	genes	that	are	within	10000	base	pairs	of	both	ends	of	
the	peak.	The	peaks	 that	did	not	map	to	a	gene	target	 that	 is	part	of	 the	PKD	Signature	









































protease	 inhibitor	 phenylmethylsulfonyl	 fluoride	 (PMSF).	 The	 tissue	was	 resuspended	 in	
cytoplasmic	lysis	buffer	and	moved	in	a	glass	tissue	grinder	(Kimble	Chase)	for	homogenisation	























were	 stained	 with	 the	 primary	 antibodies	 used	 for	 ChIP:	 rabbit	 anti-pSTAT3	 (1:75;	 Cell	
Signaling	#9145);	mouse	anti-RUNX1	 (1:250;	 Santa	Cruz	Biotechnology,	 Inc.	 #sc-365644).	
Anti-rabbit	or	anti-mouse	Envision	HRP	(Dako)	was	used	as	the	secondary	antibody.































Validation of meta-analysis in independent samples
Our	 next	 step	 was	 to	 validate	 TFs	 identified	 in	 the	 meta-analysis	 in	 independent	
experimental	groups	of	mice	during	PKD	progression	and/or	the	nephrotoxic	injury/repair	
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Figure 1. Schematic representation of the workflow used for the identification and validation of TFs involved in 
PKD and injury/repair

















involvement	of	Irf6 and JunB could	not	be	confirmed (Supplementary	Table	1,	Figure	2).	We	
also	evaluated	whether	expression	of	the	13	TFs	was	affected	by	injury,	by	comparing	DCVC	
versus	PBS	treated	animals	at	injury-related	timepoints	(1	wk,	2	wks	and	5	wks	after	DCVC	
treatment).	Of	 the	13	 selected	TFs,	8	were	part	of	 the	previously	 reported	 Injury	Repair	
profile,	while	5	were	not5.	We	confirmed	significant	injury-induced	dysregulation	(P	<	0.05)	
of	 6	 out	 of	 8	 TFs	 predicted	 to	be	 involved	 in	 the	 injury/repair	mechanism	by	 the	meta-
analysis,	while	we	did	not	see	any	significant	dysregulation	of	the	expression	of	3	out	of	5	
TFs	that	were	not	found	in	the	meta-analysis	(Supplementary	Table	1,	Figure	2)5.	Notably,	
the	expression	of	Runx1 and Stat3 was	most	significantly	affected	by	DCVC-induced	injury	
and	PKD	progression.




We	 performed	 immunohistochemical	 analysis	 for	 the	 active	 form	 of	 STAT3	 (pSTAT3)	
and	 RUNX1,	 and	 studied	 activation	 and	 subcellular	 localisation.	 In	 non-injured	 Wt	 and	
iKspPkd1del	mice,	pSTAT3	and	RUNX1	are	not	detectable,	except	 for	some	 interstitial	cells	
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STAT3 and RUNX1 target genes were dysregulated during ADPKD progression and after 
injury
Although	 we	 demonstrated	 that	 pSTAT3	 and	 RUNX1	 expression	 were	 increased	 during	
ADPKD	progression	and	after	injury,	both	at	gene	and	protein	level,	we	do	not	know	if	this	
would	 translate	 into	 differences	 in	 their	 activity	 as	 transcriptional	 regulators.	 Thus,	 we	









The	final	targets	we	selected	are	Scp2, Kif22, Stat3 (autoregulation)	and	Socs3	for	STAT3,	and	
Runx1 (autoregulation), Tnfrsf12a and Bcl3	as	targets	for	RUNX1.	We	checked	the	expression	
of	 these	 targets	after	 injury	and	during	PKD	progression	 in	 iKspPkd1del	 and	Wt	mice.	We	
found	that,	 in	 iKspPkd1del	mice,	all	 targets	were	significantly	upregulated	except	for	Scp2, 
which	was	downregulated,	suggesting	an	inhibitory	effect	of	STAT3	on	Scp2	transcription.	




STAT3 and RUNX1 ChIP-qPCR in murine renal epithelial cells
To	confirm	that	STAT3	and	RUNX1	are	directly	 regulating	 the	expression	of	 the	 indicated	
target	genes	in	the	renal	epithelium,	we	performed	chromatin	immunoprecipitation	(ChIP)	
analysis	 followed	 by	 quantitative	 PCR	 (ChIP-qPCR).	 We	 first	 confirmed	 that	 STAT3	 and	
RUNX1	were	expressed	in	mIMCD3	cells	(Supplementary	Fig	3).	We	then	isolated	chromatin	
and	performed	ChIP-qPCR.	 STAT3	enrichment	at	 the	promoter	 region	of	 the	Scp2, Kif22, 





STAT3 and RUNX1 ChIP-qPCR in murine kidney tissue
We	then	investigated	whether	binding	of	STAT3	and	RUNX1	at	the	promoter	region	of	their	
target	genes	 is	 increased	 in	 cystic	kidneys	 compared	 to	non-cystic	kidneys.	 To	do	 so,	we	
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Figure 4. Identification of STAT3 and RUNX1 target genes
(a) STAT3	 and	RUNX1	emerged	 as	 two	 leading	 candidates	 for	wet-lab	 validation.	Using	 Cistrome	database,	we	
identified	ChIP-peaks	that	were	used	in	the	wet-lab	validation	process	and	led	to	the	identification	of	confirmed	
STAT3	 and	RUNX1	 targets. (b) Expression	 of	 STAT3	 and	 RUNX1	 targets	 during	 PKD	progression. Total	 RNA	was	
isolated	 from	kidneys	of	Wt	and	 iKspPkd1del	mice	 treated	with	PBS	or	DCVC	at	1,	2,	5,	10	weeks	and	at	kidney	
failure.	Expression	of	selected	STAT3	(Scp2, Kif22 and Socs3)	and	RUNX1	(Bcl3, Tnfrsf12a)	targets	was	evaluated	
using	a	SYBR-Green	based	qPCR.	On	the	Y-axis	normalised	Ct	values	(cycle	threshold	values)	are	plotted.	Data	were	
analysed	using	a	two-way	ANOVA	test	based	on	comparing	Treatment	(DCVC	vs	PBS)	and	Genotype	(iKspPkd1del 

















































































































Figure 5. ChIP validation of pSTAT3 and RUNX1 targets in mIMCD3 cells
(a)	ChIP	with	anti-pSTAT3	antibody	showed	significant	enrichment	at	the	promoter	region	of	Scp2, Kif22, Stat3 and 
Socs3	compared	to	a	negative	control	antibody	(rIgG)	and	a	non-binding	region	(Neg).	(b)	ChIP	with	anti-RUNX1	








As	expected,	we	observed	a	significantly	increased	abundance	of	STAT3	at	Stat3, Socs3, Scp2 
and Kif22	promoter	regions	in	iKspPkd1del	mice	compared	to	Wt	(Figure	6a	-	more	severe	
iKspPkd1del	+	DCVC	and	Supplementary	Figure	4a	-	milder	iKspPkd1del	+	PBS).
RUNX1	 enrichment	 in	 iKspPkd1del	 mice	 was	 not	 significantly	 higher	 than	 in	 Wt	 mice.	
However,	 RUNX1	 enrichment	was	 significantly	 higher	 compared	 to	 IgG	 at	 the	 promoter	
region	of	Runx1 and Bcl3	in	iKspPkd1del	mice	but	not	in	Wt.	A	similar	trend	is	observed	for	
Tnfrsf12a.	This	means	that	in	iKspPkd1del	mice,	RUNX1	binding	is	specific	while	in	Wt	it	is	not	
different	from	the	background	signal.	Thus,	RUNX1	 is	actively	binding	 its	 targets	 in	cystic	
kidneys	only.	(Figure	6b	-	more	severe	iKspPkd1del	+	DCVC	and	Supplementary	Figure	4b	-	
milder iKspPkd1del	+	PBS).
Overall,	 these	data,	 in	addition	to	the	altered	expression	 levels,	show	that	the	activity	of	
STAT3	and	RUNX1	is	increased	in	advanced	stages	of	PKD	in	mice.








These	data	suggest	 that	 the	TFs	 identified	by	our	meta-analysis	using	 rodent	models	are	
relevant	for	human	ADPKD.



















































































































Figure 6. Increased binding of STAT3 and RUNX1 to the promoter of target genes in cystic kidneys, shown by 
ChIP-qPCR
ChIP-qPCR	analysis	of	end-stage	renal	disease	iKspPkd1del	kidneys	or	Wt	kidneys	at	24	weeks	after	DCVC.	(a)	We	




















Using MSigDB,	 we	 identified	 92	 TFs	 in	 the	 PKD	 Signature	 and	 again	 showed	 that	 about	
35%	of	these	genes	(32	out	of	92)	have	a	strong	injury-related	component.	This	 is	 in	 line	







































revealed	enrichment	 for	pathways	known	 to	play	a	 role	 in	PKD	progression,	 such	as	 the	
TGF-β	pathway,	oxidative	stress,	cellular	metabolism,	interleukins	signalling,	adipogenesis,	




TRIM28)38,39,	 renal	 injury	 and	fibrosis	 (EGR1)26,	 epithelial	 cell	 proliferation,	 apoptosis	 and	
adhesion	 (TP63)40.	 Nevertheless,	 apart	 from	 STAT3,	 the	 TFs	 themselves	 had	 never	 been	
associated	with	PKD	before	and	therefore	could	be	interesting	subjects	for	future	studies.	
Surprisingly,	we	did	 not	 find	back	RUNX1	 in	 this	 list	 as	 the	 level	 of	 enrichment	was	 just	
below	the	significance	threshold	(data	not	shown).	Nevertheless,	we	confirmed	increased	





To	 further	 test	 and	 validate	 our	 approach,	we	 selected	 for	 additional	wet-lab	 validation	
STAT3	and	RUNX1	as	they	showed	the	most	significant	change	 in	expression	both	 in	PKD	
progression	and	injury. By	performing	ChIP-qPCR	for	STAT3	and	RUNX1	in	ADPKD-affected	





























We	 observed	 increased	 expression	 of	 STAT3	 and	 RUNX1	 also	 after	 injury	 in	 Wt	 mice,	






To	 conclude,	 our	 comprehensive	 analyses	 identified	 a	 signature	 of	 TFs	 differentially	
expressed	 in	 PKD	 and	 to	 a	 certain	 extent	 also	 in	 injury/repair.	 Several	 of	 these	 TFs	 are	






















Compliance with ethical standards
Conflict of interest
The	authors	declare	no	competing	financial	interests.





kidney	disease.	J Clin Invest 124,	2315-2324,	doi:10.1172/JCI72272	(2014).
2	 Leonhard,	W.	N.,	Happe,	H.	&	Peters,	D.	J.	Variable	Cyst	Development	in	Autosomal	Dominant	Polycystic	
Kidney	Disease:	The	Biologic	Context.	J Am Soc Nephrol 27,	3530-3538,	doi:10.1681/ASN.2016040425	
(2016).
3	 Patel,	V. et al.	Acute	kidney	injury	and	aberrant	planar	cell	polarity	induce	cyst	formation	in	mice	lacking	
renal	cilia.	Hum Mol Genet 17,	1578-1590,	doi:10.1093/hmg/ddn045	(2008).
4	 Happe,	 H. et al.	 Toxic	 tubular	 injury	 in	 kidneys	 from	 Pkd1-deletion	 mice	 accelerates	 cystogenesis	
accompanied	 by	 dysregulated	 planar	 cell	 polarity	 and	 canonical	Wnt	 signaling	 pathways.	Hum Mol 
Genet 18,	2532-2542,	doi:10.1093/hmg/ddp190	(2009).
5	 Malas,	 T.	 B. et al.	 Meta-analysis	 of	 polycystic	 kidney	 disease	 expression	 profiles	 defines	 strong	








8	 Lachmann,	A. et al.	ChEA:	transcription	factor	regulation	inferred	from	integrating	genome-wide	ChIP-X	
experiments.	Bioinformatics 26,	2438-2444,	doi:10.1093/bioinformatics/btq466	(2010).
9	 Stockel,	D. et al.	Multi-omics	enrichment	analysis	using	the	GeneTrail2	web	service.	Bioinformatics 32, 
1502-1508,	doi:10.1093/bioinformatics/btv770	(2016).
10	 Ritchie,	M.	E. et al.	limma	powers	differential	expression	analyses	for	RNA-sequencing	and	microarray	
studies.	Nucleic Acids Res 43,	e47,	doi:10.1093/nar/gkv007	(2015).
11	 Mei,	 S. et al.	 Cistrome	Data	Browser:	 a	data	portal	 for	ChIP-Seq	and	 chromatin	accessibility	data	 in	
human	and	mouse.	Nucleic Acids Res 45,	D658-D662,	doi:10.1093/nar/gkw983	(2017).
12	 Karolchik,	D.,	Hinrichs,	A.	S.	&	Kent,	W.	J.	The	UCSC	Genome	Browser.	Curr Protoc Bioinformatics Chapter 
1,	Unit1	4,	doi:10.1002/0471250953.bi0104s28	(2009).
13	 Lantinga-van	Leeuwen,	I.	S. et al.	Lowering	of	Pkd1	expression	is	sufficient	to	cause	polycystic	kidney	
disease.	Human Molecular Genetics 13,	3069-3077,	doi:10.1093/hmg/ddh336	(2004).
14	 Lantinga-van	 Leeuwen,	 I.	 S. et al.	 Kidney-specific	 inactivation	 of	 the	 Pkd1	 gene	 induces	 rapid	 cyst	
formation	in	developing	kidneys	and	a	slow	onset	of	disease	in	adult	mice.	Hum Mol Genet 16,	3188-
3196,	doi:10.1093/hmg/ddm299	(2007).






17	 Leonhard,	W.	N. et al.	Curcumin	inhibits	cystogenesis	by	simultaneous	interference	of	multiple	signaling	
pathways:	in	vivo	evidence	from	a	Pkd1-deletion	model.	Am J Physiol Renal Physiol 300,	F1193-1202,	
doi:10.1152/ajprenal.00419.2010	(2011).
18	 Trudel,	M.,	Dagati,	V.	&	Costantini,	F.	C-Myc	as	an	 Inducer	of	Polycystic	Kidney-Disease	 in	Transgenic	
Mice.	Kidney Int 39,	665-671,	doi:DOI	10.1038/ki.1991.80	(1991).
19	 Leonhard,	 W.	 N. et al.	 Scattered	 Deletion	 of	 PKD1	 in	 Kidneys	 Causes	 a	 Cystic	 Snowball	 Effect	 and	
Recapitulates	Polycystic	Kidney	Disease.	Journal of the American Society of Nephrology 26,	1322-1333,	
doi:10.1681/Asn.2013080864	(2015).
20	 Takakura,	A. et al.	Pyrimethamine	inhibits	adult	polycystic	kidney	disease	by	modulating	STAT	signaling	
pathways.	Hum Mol Genet 20,	4143-4154,	doi:10.1093/hmg/ddr338	(2011).
21	 Hassane,	S. et al.	Elevated	TGFbeta-Smad	signalling	in	experimental	Pkd1	models	and	human	patients	
with	polycystic	kidney	disease.	J Pathol 222,	21-31,	doi:10.1002/path.2734	(2010).
22	 Lu,	 D. et al.	 Loss	 of	 Glis2/NPHP7	 causes	 kidney	 epithelial	 cell	 senescence	 and	 suppresses	 cyst	
growth	 in	 the	Kif3a	mouse	model	of	 cystic	kidney	disease.	Kidney Int 89,	 1307-1323,	doi:10.1016/j.
kint.2016.03.006	(2016).
23	 Le,	N.	H. et al.	Increased	activity	of	activator	protein-1	transcription	factor	components	ATF2,	c-Jun,	and	
c-Fos	in	human	and	mouse	autosomal	dominant	polycystic	kidney	disease.	J Am Soc Nephrol 16, 2724-
2731,	doi:10.1681/ASN.2004110913	(2005).
24	 Zhou,	 X. et al.	 Sirtuin	 1	 inhibition	 delays	 cyst	 formation	 in	 autosomal-dominant	 polycystic	 kidney	
disease.	J Clin Invest 123,	3084-3098,	doi:10.1172/JCI64401	(2013).
25	 Lakhia,	 R. et al.	 PPARalpha	 agonist	 fenofibrate	 enhances	 fatty	 acid	 beta-oxidation	 and	 attenuates	
polycystic	kidney	and	 liver	disease	 in	mice.	Am J Physiol Renal Physiol 314,	F122-F131,	doi:10.1152/
ajprenal.00352.2017	(2018).
26	 Ho,	L.	C. et al.	Egr-1	deficiency	protects	from	renal	inflammation	and	fibrosis.	J Mol Med (Berl) 94, 933-
942,	doi:10.1007/s00109-016-1403-6	(2016).
27	 Fujiu,	 K.,	 Manabe,	 I.	 &	 Nagai,	 R.	 Renal	 collecting	 duct	 epithelial	 cells	 regulate	 inflammation	 in	





Disease.	Results Probl Cell Differ 60,	323-344,	doi:10.1007/978-3-319-51436-9_12	(2017).
30	 Shannon,	 M.	 B.,	 Patton,	 B.	 L.,	 Harvey,	 S.	 J.	 &	 Miner,	 J.	 H.	 A	 hypomorphic	 mutation	 in	 the	 mouse	
laminin	alpha5	gene	causes	polycystic	kidney	disease.	J Am Soc Nephrol 17,	1913-1922,	doi:10.1681/
asn.2005121298	(2006).
31	 Lee,	K.,	Boctor,	S.,	Barisoni,	L.	M.	&	Gusella,	G.	L.	Inactivation	of	integrin-beta1	prevents	the	development	
of	polycystic	kidney	disease	after	the	loss	of	polycystin-1.	J Am Soc Nephrol 26,	888-895,	doi:10.1681/
ASN.2013111179	(2015).
32	 Tao,	Y.	X.,	Zafar,	I.,	Kim,	J.,	Schrier,	R.	W.	&	Edelstein,	C.	L.	Caspase-3	gene	deletion	prolongs	survival	in	
polycystic	 kidney	disease.	 Journal of the American Society of Nephrology 19,	 749-755,	 doi:10.1681/
Asn.2006121378	(2008).




disease	research	and	therapy.	Nat Rev Nephrol 14,	678-687,	doi:10.1038/s41581-018-0051-1	(2018).
34	 Merta,	M. et al.	Cytokine	profile	 in	autosomal	dominant	polycystic	kidney	disease.	Biochemistry and 
molecular biology international 41,	619-624	(1997).
35	 Stringer,	K.	D. et al.	Gender	hormones	and	the	progression	of	experimental	polycystic	kidney	disease.	
Kidney Int 68,	1729-1739,	doi:DOI	10.1111/j.1523-1755.2005.00589.x	(2005).
36	 Talbot,	J.	J. et al.	Polycystin-1	regulates	STAT	activity	by	a	dual	mechanism.	Proc Natl Acad Sci U S A 108, 
7985-7990,	doi:10.1073/pnas.1103816108	(2011).
37	 Weijts,	B.	G. et al.	E2F7	and	E2F8	promote	angiogenesis	through	transcriptional	activation	of	VEGFA	in	
cooperation	with	HIF1.	The EMBO journal 31,	3871-3884,	doi:10.1038/emboj.2012.231	(2012).
38	 Carvajal,	 L.	A.,	Hamard,	P.-J.,	Tonnessen,	C.	&	Manfredi,	 J.	 J.	E2F7,	a	novel	 target,	 is	up-regulated	by	
p53	and	mediates	DNA	damage-dependent	transcriptional	repression.	Genes & Development 26,	1533-
1545,	doi:10.1101/gad.184911.111	(2012).
39	 Iyengar,	S.	&	Farnham,	P.	J.	KAP1	protein:	an	enigmatic	master	regulator	of	the	genome.	J Biol Chem 286, 
26267-26276,	doi:10.1074/jbc.R111.252569	(2011).
40	 Carroll,	D.	K.,	Brugge,	J.	S.	&	Attardi,	L.	D.	p63,	cell	adhesion	and	survival.	Cell cycle (Georgetown, Tex.) 6, 
255-261,	doi:10.4161/cc.6.3.3799	(2007).
41	 Liu,	J. et al.	Role	of	Stat3	Signaling	in	Control	of	EMT	of	Tubular	Epithelial	Cells	During	Renal	Fibrosis.	Cell 
Physiol Biochem 42,	2552-2558,	doi:10.1159/000480216	(2017).
42	 Nechemia-Arbely,	Y. et al.	IL-6/IL-6R	axis	plays	a	critical	role	in	acute	kidney	injury.	J Am Soc Nephrol 19, 
1106-1115,	doi:10.1681/ASN.2007070744	(2008).
43	 Xiao,	Z. et al.	Cilia-like	structures	and	polycystin-1	in	osteoblasts/osteocytes	and	associated	abnormalities	
in	skeletogenesis	and	Runx2	expression.	J Biol Chem 281,	30884-30895,	doi:10.1074/jbc.M604772200	
(2006).
44	 Pozner,	A. et al.	Developmentally	regulated	promoter-switch	transcriptionally	controls	Runx1	function	




46	 Tang,	 X. et al.	 Runt-Related	 Transcription	 Factor	 1	 Regulates	 LPS-Induced	 Acute	 Lung	 Injury	 via	NF-
kappaB	Signaling.	Am J Respir Cell Mol Biol 57,	174-183,	doi:10.1165/rcmb.2016-0319OC	(2017).
47	 Umansky,	K.	B. et al.	Runx1	Transcription	Factor	Is	Required	for	Myoblasts	Proliferation	during	Muscle	
Regeneration.	Plos Genet 11,	e1005457,	doi:10.1371/journal.pgen.1005457	(2015).
48	 Logan,	T.	T.,	Villapol,	S.	&	Symes,	A.	J.	TGF-beta	superfamily	gene	expression	and	induction	of	the	Runx1	
transcription	 factor	 in	adult	neurogenic	 regions	after	brain	 injury.	PLoS One 8,	e59250,	doi:10.1371/
journal.pone.0059250	(2013).
49	 Zhou,	T. et al.	Runt-Related	Transcription	Factor	1	(RUNX1)	Promotes	TGF-beta-Induced	Renal	Tubular	
Epithelial-to-Mesenchymal	 Transition	 (EMT)	 and	Renal	 Fibrosis	 through	 the	PI3K	 Subunit	 p110delta.	
EBioMedicine 31,	217-225,	doi:10.1016/j.ebiom.2018.04.023	(2018).
50	 Zhang,	G. et al.	 Long	non-coding	RNA	FENDRR	reduces	prostate	cancer	malignancy	by	competitively	
CHAPTER 5
150
binding	 miR-18a-5p	 with	 RUNX1.	 Biomarkers 23,	 435-445,	 doi:10.1080/1354750X.2018.1443509	
(2018).























Supplementary Figure 2. Overview of pSTAT3 and RUNX1 expression in Wt and iKspPkd1del mice after injury and 
during cyst progression
(a)	Low	magnification	of	Wt	and	 iKspPkd1del	kidneys	at	1	week	after	DCVC	(+	 injury)	or	PBS	(-	 injury).	With	this	
magnification,	 it	 is	possible	to	appreciate	that	the	expression	of	pSTAT3	and	RUNX1	in	non-injured	kidneys	was	
present	mainly	 in	some	interstitial	cells	while	after	 injury	the	expression	was	clearly	visible	 in	the	nuclei	of	the	
epithelial	cells	(brown	nuclei).	In	particular,	tubules	in	the	cortico-medullary	region,	which	are	more	sensitive	to	
the	toxic	insult,	showed	the	most	staining.	(b)	Low	magnification	of	Wt	and	iKspPkd1del	kidneys	at	10	weeks	after	
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Supplementary Figure 3. Gene and protein expression of the TFs in cells






Supplementary Figure 4. 
Enrichment of STAT3 and 
RUNX1 at their targets in Wt 
and iKspPkd1del mice treated 
with PBS
ChIP-qPCR	 analysis	 of	 end-
stage	 renal	 disease	 iKspPkd1del 
kidneys	(median	21	weeks	after	
PBS,	 equals	 age	 8	 months)	 or	
Wt	 kidneys	 (24	 weeks	 after	
PBS,	 equals	 age	 9	 months).	 (a) 
We	 confirmed	 an	 increased	
enrichment	 for	 STAT3	 at	 the	
promoter	 region	 of	 their	 target	
genes.	 (b) RUNX1	 enrichment	
at its targets is not detected in 
Wt	samples	but	show	a	trend	in	
iKspPkd1del	 samples.	 The	 Y-axis	
shows	 the	 input-normalised	
binding-enrichment	 of	 the	 TFs	
to	the	indicated	genomic	region.	
Data	 represent	 the	 mean	 of	
two	 independent	 ChIPs	 ±	 SD;	
Two-way	 ANOVA	 with	 Tukey’s	





Supplementary Figure 5. Overview of pSTAT3 and RUNX1 expression in human kidneys with ADPKD
Low	magnification	 of	 healthy	 and	ADPKD	 affected	 human	 kidneys	 showing	 that	 the	 expression	 of	 pSTAT3	 and	
RUNX1	was	present	mainly	in	some	interstitial	cells	while	cyst-lining	epithelial	cells,	epithelial	cells	of	surrounding	
tubules	and	infiltrating	cells	showed	clear	nuclear	pSTAT3	and	RUNX1	staining	(brown	nuclei).	Scale	bars	100	µm.
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Autosomal	 Dominant	 Polycystic	 Kidney	Disease	 (ADPKD)	 progression	 involves	 a	 complex	
interaction	of	different	molecular	pathways,	ultimately	leading	to	cyst	growth	and	loss	of	
kidney	function.	The	exact	mechanism	behind	cyst	formation	is	still	not	clearly	understood.	
Moreover,	 we	 know	 some	 of	 the	 molecular	 pathways	 involved	 in	 cyst	 initiation	 and	
progression,	but	we	do	not	know	at	which	stage	of	the	disease	they	play	a	role.




























of	 	Fjx1,	 suggesting	that	some	of	 the	pathways	 involved	 in	 response	to	 injury	are	crucial	
in	cyst	formation	and	progression.	At	the	same	time,	we	observed	that	the	inflammatory	




induced	by	 cyst	growth	and	compression,	are	 in	part	dependent	on	Fjx1	 expression	and	
do	not	 influence	 cyst	 formation	 significantly.	However,	 they	did	 impact	 the	 functionality	
of	 the	 cystic	 kidneys	 and	 the	 survival	 of	 the	animal.	Altogether,	 our	 results	 suggest	 that	
Fjx1	 regulates	pathways	related	to	the	fibrotic	response	and	that	these	are	critical	 in	the	
advanced	 stages	of	 the	disease,	more	 than	 in	 cyst	 initiation	and	expansion.	 Such	 results	






We	found	reduced	expression	of	Tgfb1	and	three	targets	genes	(Pdgfb, Fn1 and Col1a117-19)	






















Another	 consideration	 is	 that	 YAP	 and	 TAZ	 have	 mostly	 overlapping	 yet	 also	 unique	









To	 complicate	 the	picture	 further,	 YAP	and	TAZ	are	at	 the	 crossroad	of	 several	 signalling	
pathways,	 such	 as	 TGFβ	 and	 WNT	 pathways.	 When	 phosphorylated,	 YAP	 and	 TAZ	 are	
restrained	in	the	cytoplasm	of	the	cell,	where	they	can	interact	with	SMADs	and	β-catenin	






fibronectin	 (Fn1),	plasminogen	activator	 inhibitor-1	 (Pai1)	and	matrix	metallopeptidase	2	
(Mmp2).	Therefore,	our	results	show	that	reduction	of	YAP	results	in	increased	activation	
of	 the	WNT	pathway	 target	MYC,	 known	 to	 be	 a	 critical	 player	 in	 PKD30,31,	 and	 of	 some	








revealed that Yap	 KO	 resulted	 in	 impaired	 expression	 of	 integrins,	 which	 are	 important	
for	 the	 interaction	of	 the	cells	with	 the	ECM	and	 the	correct	establishment	of	 the	cystic	
structures.	 As	 a	 consequence,	 Yap	 KO	 cells	 were	 able	 to	 form	 cysts	 only	 sporadically.	
However,	 the	 sporadic	 cysts	 could	 grow	 normally,	 suggesting	 that	 proliferation	 was	 not	
affected.	Consistently,	in vivo,	we	did	not	observe	any	effect	on	proliferation	after	Yap	ASO	
treatment.	























Additionally,	 we	 compared	 our	 PKD	 Signature	 with	 a	 study	 focused	 on	 macrophage	




















computational	 approaches,	 we	 interrogated	 the	 signature	 in	 different	 ways.	 First	 of	 all,	
we	 defined	 the	 list	 of	 TFs	 dysregulated	 in	 PKD	 using	MsigDB,	 and	 identified	 those	with	
an	 involvement	 in	 injury-repair.	Several	of	 the	TFs	 identified	were	already	known	 in	PKD,	
proving	 the	 validity	 of	 our	 approach.	 At	 the	 same	 time,	 we	 identified	 many	 other	 TFs	
never	described	 in	PKD	before,	which	might	be	 interesting	candidates	 for	 future	studies.	
Subsequently,	 employing	 the	 ChEA	 2016	 database	 of	 TFs	 targets,	we	 predicted	 TFs	 that	
are	 relevant	 to	PKD	based	on	 the	enrichment	of	 their	 targets	 in	 the	PKD	Signature.	This 
method	allowed	us	to	identify	TFs	that	were	missing	in	the	signature,	maybe	because	their	
expression	 level	 is	 not	 changed	 in	 PKD.	 Nevertheless,	 their	 activity	 is	 likely	 changed,	 as	






To	 validate	 our	 approach,	 we	 focused	 on	 two	 TFs	 for	 further	 wet-lab	 experiments.	We	
selected	 STAT3	 and	 RUNX1	 as	 they	 showed	 the	 most	 significant	 change	 in	 expression,	
both	in	PKD	progression	and	injury.	We	confirmed	that	the	expression	of	the	TFs	and	their	










































initiation	 and	 growth.	However,	 I	 believe	 that	 injury-repair	must	 be	 considered	more	 as	
a	means	to	understand	the	 initial	phases	of	cystogenesis	more	than	a	possible	target	for	
therapy.	 Indeed,	even	 though	 injury-repair	mechanisms	are	 involved	 in	PKD	progression,	
some	 of	 the	 biological	 functions	 they	 control	 are	 actually	 employed	 to	 cope	 with	 the	
alterations	taking	place	during	disease	progression.	
In	my	opinion,	particular	attention	should	be	given	to	the	elucidation	of	 the	early	stages	
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Autosomaal	 dominant	 overervende	 cystenieren,	 in	 het	 Engels	 Autosomal	 Dominant	
Polycystic	Kidney	Disease	(ADPKD),	is	een	systemische	ziekte	die	meestal	wordt	veroorzaakt	




renale	 ziektemanifestaties,	 zoals	 cystevorming	 in	 de	 lever	 en	 alvleesklier,	 en	 vasculaire	
afwijkingen.	Momenteel	 is	 er	 geen	medicijn	 dat	 ADPKD	 kan	 genezen,	 en	 daarom	 is	 het	
van	 groot	 belang	 om	 beter	 inzicht	 te	 krijgen	 in	 de	mechanismen	 die	 betrokken	 zijn	 bij	
cystevorming,	cystegroei	en	ziekteprogressie.
In	 patiënten	met	ADPKD	nemen	de	 cysten	 gedurende	het	 leven	 toe,	 zowel	 in	 aantal	 als	
in	grootte.	De	cellen	die	de	cystewand	bekleden	delen	actief,	en	scheiden	vloeistof	uit	 in	
het	 lumen	van	de	cyste,	wat	bijdraagt	aan	de	groei.	Cystegroei	en	expansie	veroorzaken	
mechanische	 stress	 in	 het	 omliggende	 weefsel.	 Dit	 gaat	 gepaard	 met	 de	 secretie	 van	
cytokines	 en	 groeifactoren,	 welke	 infiltrerende	 cellen	 aantrekken.	 Deze	 zorgen	 weer	






progressie	 beschreven.	 Op	 basis	 van	 deze	 aanname	 is	 het	 doel	 van	 dit	 proefschrift	 om	
de	moleculaire	mechanismen	 betrokken	 bij	 zowel	 schade-herstel	 van	 de	 nier	 als	 ADPKD	
progressie	te	bestuderen,	om	zo	de	ontwikkeling	van	de	ziekte	beter	te	begrijpen	en	nieuwe	
inzichten	voor	toekomstige	studies	en	therapeutische	behandelingen	te	krijgen.





epitheelcellen	 controleert	 en	 Hippo	 signalering,	 die	 orgaangrootte	 controleert.	 In	 een	









de	Hippo	pathway.	 Echter,	we	 zagen	wel	 een	beschermend	effect	 van	Fjx1	 uitschakeling	
op	fibrose	en	de	 infiltratie	van	 immuuncellen.	Dit	zorgde	ervoor	dat	de	muizen	 langer	 in	
leven	bleven,	wat	suggereert	dat	de	modulatie	van	de	fibrotische	respons	kan	helpen	in	het	
controleren	van	de	ziekteprogressie.
In hoofdstuk 3	 doen	 we	 verder	 onderzoek	 naar	 de	 rol	 van	 de	 Hippo	 pathway	 in	 PKD	
progressie.	 De	 Hippo	 pathway	 is	 een	 sterk	 geconserveerde	 signaaloverdrachtsroute	 die	
orgaangrootte	reguleert.	Meerdere	moleculaire	mechanismen	die	door	de	Hippo	pathway	
















voor	 ADPKD,	 gecombineerd	met	 genexpressieprofielen	 die	 openbaar	 beschikbaar	 zijn	 in	
de	literatuur,	om	zo	een	lijst	van	genen	te	identificeren	die	ontregeld	zijn	in	PKD	(de	‘PKD	
Signature’).	 Bovendien	 hebben	 we	 de	 link	 tussen	 PKD	 progressie	 en	 nierschade-herstel	
mechanismen	 onderzocht	 door	 de	 ‘PKD	 Signature’	 te	 vergelijken	met	 nierschade-herstel	









hebben	we	 onze	 selectie	 gevalideerd	met	 laboratoriumexperimenten.	Met	 verschillende	
technieken	 hebben	we	 aangetoond	 dat	 twee	 TFs	 (STAT3	 en	RUNX1)	 actiever	 zijn	 tijdens	
nierschade	én	in	cystenieren,	vergeleken	met	normale	nieren,	in	zowel	muizen	als	patiënten.	












Clinico	 Humanitas	 where	 she	 studied	 the	 regulation	 of	 tetraspanin-like	 molecules	 by	
glucocorticoids	 in	 human	macrophages,	 under	 the	 supervision	 of	 Prof.	 Massimo	 Locati.	
Afterwards,	 she	 enrolled	 in	 the	Master	 program	 “Medical	 Biotechnology	 and	Molecular	
Medicine	 –	 Curriculum:	 Transplantology,	 Medical	 Immunobiotechnologies	 and	 Tissue	
Engineering”	at	the	University	of	Milan	and	graduated	cum laude	 in	2011.	As	part	of	her	
Master	 thesis,	 she	did	a	12-months	 internship	characterizing	 the	 immunophenotype	and	













Reducing YAP expression in Pkd1 mutant mice does not improve the cystic phenotype
Formica C,	Kunnen	S,	Dauwerse	JG,	Mullick	AE,	Dijkstra	KL,	Scharpfenecker	M,	Peters	DJM.
J Cel Mol Med 2020; 10.1111/jcmm.15512
Molecular pathways involved in injury-repair and ADPKD progression.
Formica C,	Peters	DJM.
Cell Signal. 2020 Aug;72:109648.
Characterisation of transcription factor profiles in polycystic kidney disease (PKD): 
identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD 
progression.
Formica C*,	Malas*	T,	Balog	J,	Verburg	L,	‘t	Hoen	PAC,	Peters	DJM.
J Mol Med. 2019 Dec;97(12):1643-1656. 
Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury.
Formica C,	Happé	H,	Veraar	KA,	Vortkamp	A,	Scharpfenecker	M,	McNeill	H,	Peters	DJM.
J Pathol. 2019 Sep;249(1):114-125.
Comparative transcriptomics of shear stress treated Pkd1-/- cells and pre-cystic kidneys 
reveals pathways involved in early polycystic kidney disease.
Kunnen	SJ,	Malas	TB,	Formica C,	Leonhard	WN,	‘t	Hoen	PAC,	Peters	DJM.
Biomed Pharmacother. 2018 Dec;108:1123-1134.
Meta-analysis of polycystic kidney disease expression profiles defines strong involvement 
of injury repair processes.
Malas	TB*,	Formica C*,	Leonhard	WN,	Rao	P,	Granchi	Z,	Roos	M,	Peters	DJM,	‘t	Hoen	PA.
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F806-F817
Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and 
myelodysplastic syndromes: impact of patient characteristics and timing of transplant.
Spina	F,	Alessandrino	PE,	Milani	R,	Bonifazi	F,	Bernardi	M,	Luksch	R,	Fagioli	 F,	Formica C, 
Farina	L.












































Thanks	 to	 the	Little	 Italy	of	 the	Netherlands:	Luca,	Enrico,	Marida,	 Jasmine,	Felice,	Sofia,	
Anna	and	Marta.	Moving	to	a	new	country	is	always	scary	and	it	is	nice	to	have	someone	
who	understands	the	struggle	and	misses	the	Italian	food	as	much	as	you	do.
Nicola,	 Martina,	 Giulia	 and	 Giulia,	 from	 where	 should	 I	 start?	 Nicola,	 you	 have	 been	
particularly	crucial	in	these	years	as	we	shared	the	same	tough	experience	of	doing	a	PhD	












wait	 to	 come	back	 to	 you.	Domenico,	we	 shared	 the	 last	eleven	years.	 For	better	or	 for	
worse,	you	are	definitely	an	important	part	of	this	journey,	thank	you	for	your	help.	
Last	 but	 not	 least,	 I	 want	 to	 thank	 my	 family.	 Thanks	 to	 my	 uncle,	 aunt	 and	 cousins.	
Alessandra	and	Marco,	thank	you	for	your	support,	I	adore	you	both.	Mum	and	Dad,	I	owe	
you	everything;	I	am	sorry	I	moved	so	far	but	thanks	for	never	interfering	with	my	decisions.
